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SUMMARY 
Pancreatic ductal adenocarcinoma (PDAC) is by far the most common type of pancreatic 
cancer. It constitutes about 90% of tumors of the exocrine pancreas. The aggressive nature of 
PDAC along with a lack of diagnostic markers contributes to high lethality of this disease, 
which is nearly identical to its incidence. Studies from malignancies such as hepatocellular 
carcinoma and cervical cancer, along with the fact that liver and pancreas are in a close 
proximity, provided a plausible basis for the hypothesis of virus association in PDAC tumor 
development. However, there have been no established reports about virus(es) associated 
with pancreatic cancer.  
The present study identified a new cancer-associated virus in human PDAC samples, called 
Meleagrid herpesvirus-1 (MeHV-1), or also known commonly as herpesvirus of turkeys, by 
two different and independent approaches: experimental genomic subtraction and digital 
microRNAome subtraction between healthy and PDAC patients. In the first approach, a 
genome-wide experimental comparison of DNA from PDAC tissues to DNA from tissues of 
healthy individuals was performed by representational difference analysis (RDA). Using this 
technique, differences in sequence composition were selectively isolated and amplified with 
very high sensitivity. Virus sequences associated with the occurrence of pancreatic cancer 
were detected by this process. The second approach, performed in parallel, involved a 
sequence analysis of the complete microRNA (miRNA) content of PDAC tissue samples. 
The sequencing data was digitally compared to databases of human and viral sequences so as 
to identify viral miRNAs. Because of the limited number of molecules, this analysis form did 
not need any experimental selection and amplification in order to achieve a sufficiently 
enough sensitivity to find viral microRNAs. The common results of the two analyses strongly 
suggested that MeHV-1 plays a crucial role in PDAC tumor progression. One of the viral 
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microRNAs – hvt-miR-H14-3p – was studied in detail at the functional level by both in vitro 
and in vivo experiments in order to define the molecular mechanism of action with regard to 
its effect on pancreatic tumor carcinogenesis. 
The key findings from this work include: 
 Identification of MeHV-1 DNA sequences in the PCR difference products (DPs) 
resulting from RDA on genomic DNA from PDAC and healthy tissues. 
 A tumor-specific MeHV-1 signature was also identified in the miRNA sequence 
analysis of tumor DNA, using an independent methodological approach. 
 RT-qPCR analyses showed that hvt-miR-H14-3p from MeHV-1 was expressed at 
significantly higher levels in PDAC and chronic pancreatitis (CP) tissues – CP being 
a chronic inflammation of the pancreas and a well-known risk factor of PDAC – than 
in healthy tissues. This observation was further verified using independent digital 
PCR platforms. 
 Metastatic and non-metastatic PDAC cell lines overexpressing hvt-miR-H14-3p 
showed a significant increase in migration and invasion compared to the respective 
controls, interestingly, without any significant change in proliferation. 
 Hvt-miR-H14-3p was found targeting cellular p27, down-regulating its expression. 
 The functional consequences of viral sequences identified in vitro could also be 
confirmed in vivo in NOD scid gamma mice. 
In conclusion, this study is very significant in elucidating functional consequences of viral 
sequences in PDAC for the definition of relevant molecular effects responsible for 
carcinogenesis. 
Zusammenfassung 
3 
ZUSAMMENFASSUNG 
Das duktale Adenokarzinom des Pankreas (PDAC) ist mit etwa 90% aller Fälle die häufigste 
Form von Krebs des exokrinen Pankreas. Aufgrund seiner sehr aggressiven Natur und dem 
Mangel an geeigneten Verfahren zur frühen Diagnose, ist die Todesrate bei PDAC nahezu 
identisch mit der Zahl der Erkrankungen. Studien an anderen Tumoren, wie etwa dem 
Leberzell- und Zervixkarzinom, und auch die Tatsache dass Leber und Pankreas dicht 
beieinander liegen, bildeten eine vage aber plausible Basis für die Hypothese, dass auch die 
Entwicklung des PDAC mit der Aktivität von Viren verknüpft sein könnte. Bisher gab es 
aber keine fundierten Berichte über eine direkte Assoziation eines Virus mit PDAC. 
In der hier beschriebenen Studie wurde mittels zweier unabhängiger Verfahren in Tumoren 
menschlicher Patienten ein Virus identifiziert, das mit dem Auftreten von PDAC assoziiert 
ist. Es handelt sich um das Meleagrid Herpesvirus-1 (MeHV-1), ein Herpesvirus des 
Truthahns. Beim ersten Verfahren wurde ein genomweiter Vergleich der DNA aus 
Krebsgeweben mit der DNA aus gesunden Geweben mittels Repräsentativer Differenz 
Analyse (RDA) durchgeführt. RDA erlaubt es, durch eine experimentelle Substraktion mit 
hoher Sensitivität Unterschiede in Genomen zu finden und selektiv zu isolieren. Durch diesen 
Prozess konnten virale Sequenzen identifiziert werden, die mit dem Auftreten des Tumors 
korrelieren. Im zweiten Ansatz wurde durch Sequenzierung analysiert, welche microRNA 
Moleküle in Patientengeweben aber nicht in gesundem Pankreas auftauchen. Da nur ein sehr 
kleiner Teil des Genoms analysiert wurde, war keine experimentelle Selektion notwendig; 
stattdessen fand diese durch einen in silico Vergleich der Sequenzergebnisse miteinander und 
mit Datenbanken menschlicher und viraler Sequenzen statt. Die unabhängig gewonnenen 
Ergebnisse beider Ansätze deuteten darauf hin, dass MeHV-1 eine wichtige Rolle in der 
PDAC Karzinogenese spielt. 
Zussamenfassung 
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Eine der viralen microRNAs – hvt-miR-H14-3p – wurde anschließend detailliert auf 
funktioneller Ebene durch in vitro wie auch in vivo Studien untersucht, um den molekularen 
Wirkmechanismus zu identifizieren, durch den die Karzinogenese des Pankreastumors 
beeinflusst wird. 
Die wichtigsten Ergebnisse der Arbeit umfassen: 
 Die Identifizierung von MeHV-1 DNA Sequenzen in den Differenz-Produkten (DPs) 
des RDA Vergleichs der genomischen DNA aus PDAC und gesunden Geweben. 
 Die Identifizierung einer tumorspezifischen MeHV-1 Signatur auch auf Ebene der 
microRNA durch ein zweites, unabhängiges Analyseverfahren. 
 Analysen mittels RT-qPCR zeigten, dass hvt-miR-H14-3p in Geweben von Patienten 
mit PDAC oder Chronischer Pankreatitis (CP) – einer chronischen Entzündung des 
Pankreas, die ein bekannter Risikofaktor für die Entwicklung von PDAC ist – 
signifikant stärker exprimiert wurde als in Geweben von gesunden Personen. Dies 
wurde durch unabhängig durchgeführtes digitales PCR bestätigt. 
 Metastatische und nicht-metastatische PDAC Zelllinien, in denen hvt-miR-H14-3p 
überexprimiert wurde, zeigten einen signifikanten Anstieg der Zell-Migration und 
Invasion, während interessanterweise kein Unterschied in der Proliferation vorlag. 
 Hvt-miR-H14-3p reduziert die Expression des zellulären Proteins p27. 
 Die Wirkung der viralen microRNA konnte in vivo in NOD scid gamma Mäusen 
bestätigt werden. 
Zusammengefasst dokumentiert diese Arbeit einen Zusammenhang zwischen PDAC und 
dem Auftreten viraler Sequenzen und zeigt einen molekularen Mechanismus, über den die 
Karzinogenes beeinflusst werden kann. 
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1. INTRODUCTION 
1.1. Cancer 
Trillions of living cells make up the human body. In a healthy human being, cells grow and 
divide to produce new cells, and die in a very controlled and programmed manner. During 
the early development of the human body, normal cells divide relatively faster to allow 
growth of the individual. After adolescence and throughout adulthood, most cells divide only 
to replace deteriorated or dying cells or to repair tissue damage. Cancer originates when the 
orderly processes that control the growth and multiplication of normal cells become amiss. 
Cancer is a collection of related diseases characterized by the uncontrolled growth of cells 
and spread of the abnormal cells to different tissues of the body, frequently resulting in death. 
Cancer is a global problem. There are various causes of cancer: some of them are external 
factors such as tobacco use, infectious organisms, chemicals, radiation, and there are also 
internal factors like inherited mutations, hormone aberration and immune disruption that 
could potentially lead to cancer. These factors may act in tandem or independently to trigger 
or promote cancer development. These changes predominantly result in alterations or 
mutations in the genetic material of cells, thus affecting their behavior. The specific factor 
and the order and speed at which multiple factors accumulate, together with the genetic 
makeup of the individual influence the rate at which cancer develops and progresses. 
During the past few years, the identity of many cancer pathways was derived from whole-
genome sequencing of tumor types, and also from the exhaustive information of genomics, 
transcriptomics, proteomics, and metabolomics. Collaborations between various international 
cancer research centers generated data to provide particular insights into the nature of cancer 
cell and its development. Early stage detection of cancer can be improved using such data, 
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but a more refined molecular classification of tumor types is also possible. They also reveal 
aberrant signaling and alterations in the cancer cells which establish a basis for targeted 
therapy. Malignant cancers are also made up of various cell populations such as fibrous, 
inflammatory, vascular, and immunological cells. Any one or more of these cell types could 
be critical to tumor development and hence may offer an approach to prevention or therapy. 
 
Figure 1: Estimated world cancer incidence proportions by major organ sites in both sexes (redrawn based on 
the original data from Stewart and Wild, World Cancer Report, 2014). 
Malfunctions in a cell by genetic mutations often lead to tumor initiation, which when 
coupled with interactions between cancer cells and their surrounding environment, known as 
the tumor microenvironment, influence the development and progression of disease. Cancer 
is a major cause of morbidity and mortality, with annually more than 14 million new cases 
and 8 million cancer-related deaths, affecting populations in all countries. More than 60% of 
the world’s cancer cases occur in Africa, Asia, and Central and South America, and these 
regions account for about 70% of cancer-related deaths (Stewart and Wild 2014). The 
diversity and distribution of cancer in the world indicates marked and extreme differences 
with respect to particular tumor types. The dedicated efforts of researchers working 
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7 
throughout the biomedical research enterprise continue to expand our knowledge of cancer. 
Such data are vital to understanding disease causes and for the development of preventive 
measures. 
 
Figure 2: The emerging hallmarks and enabling characteristics of cancer (redrawn based on the original 
illustration by Hanahan and Weinberg, 2011).  
The classic hallmarks of cancer proposed by Hanahan and Weinberg in 2000 (Hanahan and 
Weinberg 2000) comprised of six biological capabilities. During the tumor development; 
these hallmarks are acquired by various multistep processes. These hallmarks form a 
consolidating principle for streamlining the complexities of cancer. They include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis. These prominent 
hallmarks are achieved by two enabling characteristics (Hanahan and Weinberg 2011).  
Introduction 
 
8 
The first enabling characteristic is the development of genomic instability in cancer cells. It 
generates random mutations and chromosomal rearrangements. These rare genetic changes 
can coordinate hallmark capabilities. A second enabling characteristic is the inflammation of 
premalignant and malignant tumor lesions that are driven by the immune system. Some of the 
immune cells also serve to promote tumor progression through various pathways.  
Conceptual understanding of cancer in the recent years has added two emerging hallmarks to 
the existing list (Hanahan and Weinberg 2011). The capability to modify, or reprogram, 
cellular energetics in order to most effectively support neoplastic proliferation is functionally 
independent of the six core hallmarks of cancer. This reprogrammed energy metabolism is an 
emerging hallmark. Cancer cells also avoid immunological destruction particularly by T and 
B lymphocytes, macrophages, and natural killer cells, although the immune system offers a 
significant barrier to tumor formation and progression in humans. Nevertheless, highly 
immunogenic cancer cells may successfully evade immune destruction by turning off 
components of the immune system. This tumor immunoevasion is another emerging 
hallmark, whose designation as a core hallmark is yet to be established. Tumors also exhibit 
an additional facet of complexity on top of cancer cells. Tumors contain a range of recruited, 
presumably normal cells that contribute to the hallmark traits by creating the tumor 
microenvironment. Epigenetic aberrations can also be factors in both the cancer cells and the 
tumor-associated stroma. MicroRNAs have been shown to be involved in various tumor 
phenotypes (Garzon, Marcucci et al. 2010). However, the functions of the majority of 
microRNAs in our cells that dysregulate in expression during cancer are poorly understood. 
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1.2. Pancreatic Cancer 
Our research group has strong interest in studying the cancer of pancreas. Pancreatic cancer 
is a devastating and fatal disease. Early detection tests for pancreatic cancer are unsuccessful 
and patients with a localized tumor will not have recognizable symptoms. This result in late 
diagnosis of the disease after the tumor metastasizes to other organs. Pancreatic ductal 
adenocarcinoma (PDAC) is the most lethal and common type of pancreatic cancer. It is 
usually diagnosed at an advanced stage and is resistant to therapy (Ryan, Hong et al. 2014). 
The mortality rates for patients with other gastrointestinal malignancies have decreased 
consistently during the past 30 years. However, there has been no significant change in 
survival rates of patients with PDAC. Currently, more than 80% of patients suffer relapse of 
the cancer after resection of the tumor tissue (Garrido-Laguna and Hidalgo 2015). The 
following sections detail the epidemiology, risk factors, biological and genetic 
characteristics, of pancreatic cancer with respect to PDAC phenotype. 
1.2.1. PDAC is a Highly Aggressive Type of Pancreatic Cancer 
As mentioned above, PDAC contributes the major proportion of pancreatic cancer cases. A 
characteristic feature of PDAC is an abundant accumulation of stromal cells. This suggests 
their possible role in the development and progression of pancreatic cancer. Pancreatic 
stellate cells (PSCs) are predominantly responsible for producing collagenous stroma. The 
stroma exhibits cellular elements like immune cells, endothelial cells and neural cells in 
addition to extracellular matrix proteins. There is strong evidence that indicates significant 
interactions between PSCs and tumor cells. In vitro and in vivo reports suggest that these 
interactions promote local tumor growth and distant metastasis of pancreatic cancer (Apte, 
Xu et al. 2015). Stromal cells affect the delivery of oxygen and nutrients to the tumor by 
reducing vascularization. Thus stroma causes the hypoxic zones that promote metabolic 
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adaptation in the tumor cells. The aggressive nature of PDAC is partly attributed to this 
metabolic reprogramming which is further influenced by environmental constraints (Olivares 
and Vasseur 2015). 
1.2.2. Epidemiology and Risk Factors of PDAC 
The early diagnosis of PDAC is very rare in patients younger than 40 years of age. The 
median age at diagnosis of PDAC is 71 years. The worldwide incidence of pancreatic cancer 
(comprising 85% PDAC) ranges from 1 to 10 cases per 100,000 people 1. It is the eighth or 
fourth leading cause of death from cancer in men and the ninth or fourth leading cause of 
death from cancer in women worldwide or in the Western world, respectively (Ryan, Hong et 
al. 2014). The risk factors and genetic syndromes associated with pancreatic cancer are 
shown in Table 1.  
Variable Approximate Risk 
Risk factors  
Smoking 2–3 
Long-standing diabetes mellitus 2 
Nonhereditary and chronic pancreatitis 2–6 
Obesity, inactivity, or both 2 
Non–O blood group 1–2 
Genetic syndromes and associated genes — %  
Hereditary pancreatitis (PRSS1, SPINK1) 50 
Familial atypical multiple mole and melanoma 
syndrome (p16) 
10–20 
Hereditary breast and ovarian cancer syndromes 
(BRCA1, BRCA2, PALB2) 
1–2 
Peutz–Jeghers syndrome (STK11 [LKB1]) 30–40 
Hereditary nonpolyposis colon cancer (Lynch 
syndrome) (MLH1, MSH2, MSH6) 
4 
Ataxia–telangiectasia (ATM) Not Available 
Li–Fraumeni syndrome (P53) Not Availabla 
 
 
Table 1: Risk factors and inherited syndromes associated with pancreatic cancer (based on the original data set 
of Ryan et al., 2014). Values associated with risk factors are expressed as relative risks, and values associated 
with genetic syndromes are expressed as lifetime risks, as compared with the risk in the general population. 
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It is estimated that 5% to 10% of pancreatic cancers are inherited. Cigarette smoking 
accounts for around 20% of pancreatic cancers. Individuals who smoke have a twofold higher 
risk of developing pancreatic cancer than nonsmokers. The incidence of pancreatic cancer 
increases with a family history of this disease and chronic pancreatitis (CP), diabetes, obesity, 
and high alcohol consumption. Genetic syndromes such as Lynch syndrome also increase the 
risk of pancreatic cancer. Chronic infection with Hepatitis B virus, Hepatitis C virus, or 
Helicobacter pylori also make an individual susceptible for PDAC. Recent evidence also 
suggests that consumption of red or processed meat could slightly increase the risk. 
1.2.3. Biological Characteristics of PDAC 
Pathologic features of  PDAC include a high rate of activating mutations in KRAS, precursor 
lesions progression, invasion and metastasis, an extensive stromal aggregation resulting in a 
reduced vascularization and hypoxic microenvironment, reprogramming of cellular 
metabolism, and evasion of tumor immunity (Feig, Gopinathan et al. 2012). 
Extensive studies on molecular pathology and genome data have established a model of the 
PDAC progression. There are microscopic premalignant pancreatic lesions associated with 
the pancreatic ducts, which harbor similar mutations of PDAC. These lesions are called 
pancreatic intraepithelial neoplasia (PanIN). There is a stepwise progression of PanINs from 
low grade to high grade in types 1, 2, and 3, accumulating genetic alterations (Figure 3). Low 
grade PanINs, the type 1 lesions, are columnar cells and readily detectable in disease-free 
pancreas. High grade PanINs are papillary and lose polarity undergoing mitosis. They are 
detected in the pancreas with established PDAC and also in the tumor-free pancreas from 
individuals with familial predisposition to PDAC (Canto, Hruban et al. 2012). Approximately 
90% of PanINs of all grades have KRAS mutations (Kanda, Matthaei et al. 2012). High grade 
PanINs specifically associates with the mutational inactivation of the CDKN2A, p53, and 
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SMAD family member 4 (SMAD4) tumor suppressors. These data suggest that KRAS 
mutations contribute to the inception of tumor (Hustinx, Leoni et al. 2005).  
Intraductal papillary mucinous neoplasms (IPMNs) are another type of precursor lesions to 
pancreatic cancer. Even though IPMNs are asymptomatic, they are associated with an 
increased risk of invasive PDAC. IPMNs arising from the main pancreatic duct are more 
malignant than those arising from the ductal branches. IPMNs also harbor KRAS mutations 
(Wu, Matthaei et al. 2011). 
 
Figure 3: A: Precursor lesions leading to pancreatic ductal adenocarcinoma (redrawn based on the original 
illustration by Skrypek and Seuningen, 2010). B: Histopathology of healthy pancreas leading to metastatic 
PDAC (Han and Von Hoff 2013). 
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1.2.4. Genetics of PDAC 
Cancer is fundamentally caused by germline and acquired somatic mutations in oncogenes. 
Large scale sequencing of tumor tissues has led to the understanding of genetic events that 
drive pancreatic cancer. The pancreatic tumors have been deeply sequenced, providing 
greater insights into the somatic mutations (Table 2) (Jones, Zhang et al. 2008, Jiao, Shi et al. 
2011, Wu, Jiao et al. 2011, Wu, Matthaei et al. 2011). These data may eventually lead to 
better clinical management, early detection and treatment of pancreatic cancer. The 
sequencing of PDAC tissues revealed four genes, KRAS, p16/CDKN2A, TP53 and SMAD4 
that are somatically altered in more than 50% of the cases (Jones, Zhang et al. 2008). These 
genes are briefly described below: 
Tumor Type Gene(s) Prevalence Of The Alteration Comment 
Acinar cell 
carcinoma 
APC 15%  
CTNNB1 (beta-
catenin) 
5%  
Invasive ductal 
adenocarcinoma 
p16/CDKN2A 95%  
TP53 75%  
KRAS 95% KRAS mutations occur early, and 
may be a target for early detection 
SMAD4 55% SMAD4 loss associated with poor 
prognosis and widespread disease 
MLL3, TGFBR2, 
FBXW7, ARID1A, 
AIRID2, and 
ATM 
<5% 
Some of these, such as ATM, may 
be therapeutically targetable 
IPMN 
PIK3CA 10%  
p16/CDKN2A Dependent on histologic grade  
KRAS 80%  
RNF43 75% RNF43 is a marker of mucin-
producing tumors because it is 
present in both IPMNs and MCNs 
GNAS 60% GNAS is a marker of IPMNs. GNAS 
and/or KRAS mutations are present 
in >95% of all IPMNs 
TP53 Dependent on histologic grade Higher grade lesions 
SMAD4 Dependent on histologic grade Higher grade lesions 
 
Table 2: Genetic alterations in common neoplasms of the pancreas (redrawn based on the original data from 
Wolfgang et al., 2013). 
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KRAS: It is activated by point mutation in 95% of invasive PDAC (Hruban, Vanmansfeld et 
al. 1993, Jones, Zhang et al. 2008). A small GTPase protein coded by the KRAS gene plays 
an important role in cell signaling via the mitogen-activated protein kinase (MAPK) pathway. 
The point mutations in KRAS can be easily identified, as they target 3 codons (codons 12, 13, 
and 61). Loss of KRAS expression results in massive cell death and cell cycle arrest which in 
turn leads to rapid tumor regression (Slater, Langer et al. 2010). This suggests that 
KRAS mutations could form the basis for gene-based diagnostics to detect early PDAC 
phenotype (Shi, Fukushima et al. 2008).  
p16/CDKN2A: In approximately 95% of pancreatic cancers, a tumor suppressor gene on 
chromosome 9p called p16/CDKN2A gene is inactivated (Jones, Zhang et al. 2008). The loss 
of p16 function in pancreatic cancer promotes unrestricted cell growth. Hence the protein 
product of the p16/CDKN2A gene, p16, plays an important role in the regulation of the cell 
cycle. 
TP53: It is a tumor suppressor gene on chromosome 17p. In 75% of pancreatic cancers TP53 
is inactivated (Jones, Zhang et al. 2008). This gene codes for the p53 protein that plays an 
important role in responses to cellular stress, activation of DNA repair mechanisms, growth 
arrest and apoptosis. Since p53 mediates a number of important cell functions, mutation of 
the TP53 gene results in PDAC through the loss of p53 function.  
SMAD4: It is the fourth major gene that is somatically targeted in pancreatic cancer. It acts 
as a tumor suppressor gene on chromosome 18q (Hahn, Schutte et al. 1996). The protein 
product of the SMAD4 gene, Smad4, plays an important role in the transforming growth 
factor beta (TGFβ) cell signaling pathway. Mutation of SMAD4 results in poor prognosis of 
pancreatic cancer (Blackford, Serrano et al. 2009, Iacobuzio-Donahue, Fu et al. 2009). 
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There are several other genes in addition to these four major genes that undergo lower 
frequency somatic mutations in pancreatic cancer. They include genes such as – MLL3, 
TGFBR2, FBXW7, ARID1A, AIRID2, and ataxia–telangiectasia mutated gene (ATM) (Jones, 
Zhang et al. 2008, Roberts, Jiao et al. 2012). Cancers which have genetically 
inactivated ATM could be sensitive to radiation damage and to poly(ADP) ribose polymerase 
(PARP) inhibitors (Williamson, Kubota et al. 2012).  
In addition to DNA changes, there are a number changes in gene expression in pancreatic 
cancer. Overexpressed genes could be interesting in a clinical perspective since they could be 
used not only as therapeutic targets but also as biomarkers for diagnosis of PDAC (Argani, 
Iacobuzio-Donahue et al. 2001, Hassan, Bera et al. 2004, Harsha, Kandasamy et al. 2009). 
The molecular characteristics of invasive PDAC are useful to study other lesions in the 
pancreas such as PanINs. As mentioned earlier, they are precursor lesions to the infiltrating 
PDAC. PanINs are extensively studied for genetic changes contributing to the phenotype. 
PanINs have similar genetic makeup as that of PDAC invasive genotype (Maitra, Fukushima 
et al. 2005). KRAS and p16/CDKN2A mutations occur early in PanINs with low- to 
intermediate-grade dysplasia. In PanINs with high-grade dysplasia and in invasive cancer, 
TP53 and SMAD4 mutations are late events. These findings firmly establish PanINs as 
noninvasive precursors to invasive pancreatic cancer.  
Thus, analyses of molecular changes in pancreatic cancer at the DNA, RNA and protein 
identified specific genetic alterations (Table 2). Although there is such wealth of information 
about molecular genetics of pancreatic cancer, there are no real studies on a possible effect of 
integrated pathogenic foreign DNA sequences that could potentially trigger carcinogenesis 
especially in PDAC. Tumor viruses have been known to integrate into the host cell genome 
and transform the cell to a malignant phenotype. To provide a better understanding of tumor 
viruses the following sections provide a brief description to the field of tumor virology. 
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1.3. Tumor viruses 
Cancer has been well recognized as a collection of related diseases. Currently, there are 
diverse theories on mechanisms that cause cancer. However, virus infection as one of the 
etiologies was not considered until the late 20th century. Although there was substantial 
evidence for an involvement of viruses in inflammation and cancer, these hypotheses did not 
receive due credit by the scientific community. This has now changed. A recent report of the 
International Agency for Research on Cancer (IARC) estimates that approximately 16% of 
the new cancer cases are attributed to infection, the majority of which caused by viruses 
(Stewart and Wild 2014). The burden of infection is probably even significantly higher in 
less developed countries. 
1.3.1. Brief History of Tumor Virology 
Since its inception, the research on the association of tumors and viruses has provided 
groundbreaking concepts for the causes of human cancer. In 1911 Peyton Rous first 
identified an avian virus that induced tumors in chickens; the significance of his findings was 
appreciated by the scientific community after 40 years. In the 1930s and later in the 1950s, 
Richard Shope and John Bittner, and Ludwik Gross, respectively identified viruses that cause 
tumors in mammals. This created interest in the scientific community to investigate such 
similar associations between viruses and human cancers. Consequently, in the 1960s and 
1970s, the first human tumor viruses – EBV, hepatitis B virus (HBV), and human 
papillomaviruses (HPV) – were identified to play an important role in causation of the 
disease. Later in the 1980s and 1990s, the feasibility to use advanced technologies led to the 
identification of few more human tumor viruses: human T-cell leukemia virus type 1 (HTLV-
1), hepatitis C virus (HCV), and Kaposi's sarcoma associated herpesvirus (KSHV) (Javier 
and Butel 2008).  
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1.3.2. Tumor Viruses Do Not Necessarily Follow Koch’s Postulates 
Already in the early 19
th
 century, Jakob Henle assumed that microorganisms are the causative 
agents of infectious diseases (Henle 1840). In 1884, his student Robert Koch as well as 
Friedrich Loeffler formulated four postulates to establish a causal relationship between a 
pathogen and a disease (Koch 1884, Loeffler 1884). These postulates offer a general 
guideline to identify and isolate the pathogens. Koch's postulates have also influenced 
scientists to examine pathogenesis from a molecular point of view. The four postulates are: 
1. The microorganism must be found in abundance in all organisms suffering from the 
disease, but should not be found in healthy organisms. 
2. The microorganism must be isolated from a diseased organism and grown in pure 
culture. 
3. The cultured microorganism should cause disease when introduced into a healthy 
organism. 
4. The microorganism must be reisolated from the inoculated, diseased experimental 
host and identified as being identical to the original specific causative agent. 
It was soon recognized that some pathogens like Epstein - Barr virus (EBV), even though 
they did not fulfill all the criteria of the postulates, were responsible for disease. EBV is a 
common infection that can cause a rare cancer called Burkitt’s lymphoma. In general, EBV 
cannot be isolated as pure cultures in vitro or used to re-infect susceptible hosts (Koch 1942, 
Fredricks and Relman 1996). However, Werner and Gertrude Henle, and colleagues showed 
a unique property of EBV that upon infection EBV immortalizes primary B cells (Henle, 
Diehl et al. 1967). Later oncogenes of EBV were characterized (Ernberg and Klein 2007) and 
additional EBV-associated tumors were described (Saemundsen, Purtilo et al. 1981). 
Currently, a number of viruses are an accepted cause of cancer, irrespective of their 
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fulfillment of criterion in Koch's postulates. Therefore, although Koch's postulates are 
historically important and provide a guideline for microbiologic diagnosis, fulfillment of all 
four postulates is not mandatory to demonstrate disease causality particularly in relevance 
with tumor virology. Hence, Harald zur Hausen (zur Hausen 1999) proposed alternative 
criteria for defining a causal role for an infection in cancer:  
(i) Epidemiological plausibility and evidence that a virus infection represents a risk 
factor for the development of a specific tumor. 
(ii) The consistent presence and persistence of the genome of the microbe in cells of the 
tumor. 
(iii) The stimulation of cell proliferation following transfection of the genome (or 
portions of it) in corresponding tissue culture cells. 
(iv) The demonstration that the genome of the agent induces proliferation and the 
malignant phenotype of the tumor.  
The subsequent sections of this chapter exclusively address mechanistic insights of human 
tumor viruses in causing various types of cancers. 
1.3.3. Direct and Indirect Viral Tumorigenesis 
Viral cancer agents can be broadly classified into two categories: direct carcinogens and 
indirect carcinogens. Direct carcinogens express viral oncogenes that are directly involved in 
the transformation of healthy normal cells into a tumor. Direct viral carcinogens are usually 
present in cancer cells, expressing at least one active transcript to mediate tumor 
transformation. Direct carcinogenesis is observed with HPV, Merkel cell polyomavirus 
(MCV), and KSHV related cancers. Knockdown studies with the loss or down-regulation of 
viral proteins, ultimately resulting in the loss of host cancer viability (Steele, Cowsert et al. 
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1993, Tan and Ting 1995, Goodwin and DiMaio 2000, Dirmeier, Hoffmann et al. 2005, 
Godfrey, Anderson et al. 2005, Wies, Mori et al. 2008, Houben, Shuda et al. 2010) support 
direct involvement of viruses in causing cancer. Indirect carcinogens cause chronic 
inflammation by active infection leading to mutations that are tumorigenic to the healthy 
normal cells (Parsonnet 1999, Zur Hausen 2001). Indirect carcinogens include ‘hit-and-run’ 
viruses which are responsible for inflammation and thus, initiation of tumorigenesis, but the 
viral genes are lost as the tumor develops. Good examples of this type that are under 
investigation are gamma herpesviruses such as EBV (Ambinder 2000), (Stevenson, May et 
al. 2010). 
HBV, HCV and HTLV-I do not fit precisely into either of the above two categories. HBV 
and HCV induce chronic cell death and regeneration after prolonged liver cirrhosis leading to 
hepatocellular carcinoma (HCC) (Seeger and Mason 2000, Mason, Liu et al. 2010, Tsai and 
Chung 2010). Although in the majority of HBV-related cancers HBV sequences are 
integrated into the genomes of tumor cells, it still remains to be investigated if HCC cell 
proliferation is dependent on stable expression of HBV (or HCV) genes (Seeger and Mason 
2000).  
1.3.4. Dysregulation of the Cell Cycle Machinery by Viral Oncogenes  
Viral induced oncogenesis shows hallmarks such as aberrant cell proliferation and disruption 
of cell cycle checkpoints (Figure 5) (Sherr 1996, Vermeulen, Van Bockstaele et al. 2003, 
O'Nions and Allday 2004, Kumar, Saha et al. 2010). Tumor viruses replicate in the cells 
using host machinery and transform healthy normal cells to actively proliferate (O'Nions and 
Allday 2004, Kumar, Saha et al. 2010). Viral oncoproteins have a range of mechanisms to 
dysregulate cell cycle by evading checkpoints (Figure 5) (O'Nions and Allday 2004, Kumar, 
Saha et al. 2010). Viral oncogenes induce aberrant entry to S phase using interesting 
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strategies to avoid cell cycle arrest by the G1 -S and/ or G2 -M checkpoints, (Figure 5) 
(Vermeulen, Van Bockstaele et al. 2003). There is strong selection to maintain viral genes 
that can initiate tumorigenesis, as diverse viruses show remarkable similarity in mechanisms 
to target the same tumor suppressor pathways. Virus oncogenes transform host cells to 
immortalization by inactivating tumor suppressors like pRb and p53. While most of the 
human tumor viruses encode oncoproteins that target pRb and p53, the diversity of 
mechanisms with which they do so is large (Subramanian, Knight et al. 2002). Tumor viruses 
also target telomerase reverse transcriptase (TERT) (Hwang, Lee et al. 2003, Lee, Chen et al. 
2007, Palermo, Webb et al. 2008, Pantry and Medveczky 2009, Stimson, Wood et al. 2009), 
cytoplasmic PI3K–AKT–mTOR (Smith, DeWitt et al. 2000), nuclear factor-κB (NF-κB) 
(Needleman, Turk et al. 1986, Levy 1997, Cho, Baek et al. 2001, Helt and Galloway 2003), 
β-catenin (also known as CTNNB1) (Marks, Furstenberger et al. 2007) and interferon 
signaling pathways (Reddy, Hirose et al. 2000), that have roles in tumorigenesis. 
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Figure 5: Viral-oncoproteins (red) dysregulate host components (black) of cell cycle and apoptotic pathways 
(adapted from the original illustration by Saha, Kaul, Murakami, & Robertson, 2010). 
The identification of host factors that are targeted by viral oncogenes provides deep insights 
to the mechanisms through which viruses disrupt cell cycle. Genome-wide approaches (De 
Luca et al., 2003), and microarray-based analysis (Alazawi et al., 2002; Berger et al., 
2002; Vasseur et al., 2003), have already provided some novel information on functional 
interactions between viral oncogenes and host cellular components. 
1.3.5. Tumor Viruses Maintain Latency in Host Cells 
Human tumor viruses cause persistent latent infections. They generally do not replicate to 
form active infectious virus particles in tumors cells. EBV, HBV, HTLV-1, HPV16 & 18, 
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HCV, KSHV, and MCV, all have the capacity to form virions and transmit between cells. 
However, these viruses are generally latent within tumors with a diminished or completely 
stopover virus replication (Dittmer and Krown 2007). Latency by a human tumor virus 
promotes immune evasion. It allows the virus to avoid being recognized by the immune 
system. During latency, viral protein expression is turned off and the virus camouflages 
within the host cell to escape cell-mediated immune recognition. The virus exists as a naked 
nucleic acid, often integrated or as an episome, relying on host cell machinery to replicate 
later. The discovery of EBV in Burkitt’s lymphoma, mentioned earlier, also provided 
evidence that the tumor cells can indeed harbor viral DNA in episomes without being 
transmissible.  
Viruses which productively replicate often initiate cell death, a situation called as the 
cytopathic effect (CPE). This would explain the connection between virus latency and 
tumorigenesis. CPE is often nonspecific innate immune response of cells to viral infection 
rather than a virus-induced effect. When viruses recover from latency and switch to active 
virion production, it triggers innate immune signaling as the cellular DNA damage repair 
system generates virus associated molecular patterns from various viral nucleic acids 
(Belanger, Gravel et al. 2001, Efklidou, Bailey et al. 2008, Thurau, Marquardt et al. 2009). 
The innate immune response is further amplified by activation of toll-like receptor and 
interferon signaling (Desaintes, Demeret et al. 1997). These immune responses kill infected 
cells that are undergoing virus replication by lysis completing the lytic replication. Hence, 
most of the human tumor viruses maintain latency after infection and cause cancer by 
deregulating host cellular processes. 
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1.3.6. Viral microRNAs in cancer 
MicroRNAs (miRNAs) are broad class of small, silencing effector, noncoding RNA 
molecules which, in a sequence specific manner, negatively regulate gene expression. The 
initial discovery of small interfering (si)RNAs in virus infected plants, ultimately led to the 
identification of miRNAs (Hamilton and Baulcombe 1999). The miRNAs serve as genetic 
switches in cells, turning on and off the expression of a number of genes usually in a well-
orchestrated process. However, several microRNAs are aberrantly expressed in cancer cells. 
MicroRNAs have long half-life and hence serve as diagnostic markers for cancer (Habbe, 
Koorstra et al. 2009, Matthaei, Wylie et al. 2012, Wan, Shen et al. 2012).  
As mentioned earlier in the section 1.3, viruses are one of many factors that have every 
potential to cause proliferation of normal cells and transform them into malignant cells. 
Viruses develop interesting strategies through the course of evolution to surpass the immune 
system of the host, preventing infected cells from becoming apoptotic. The opinions on RNA 
silencing pathways as antiviral strategies mediated by miRNA in plants and insects has 
completely changed after the identification of miRNAs from EBV and herpesviruses. It is 
now clear that many viruses can hijack host RNA silencing machinery by producing their 
own miRNAs. Viral-encoded miRNAs can silence the host genes in both cis and trans 
manner. It helps in two ways, precise expression of viral genomes, and modification of host 
gene expression. In this chapter, the current information on viral miRNAs is very briefly 
reviewed in relation with cancer.  
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Figure 6: Viral miRNA possible modes of action (edited and redrawn based on the original illustration by 
Pfeffer & Voinnet, 2006). Individual steps in this figure are briefly discussed below. 
(1) Viral miRNAs act in a cis manner to regulate virus host genome expression and 
contribute to latency. This also helps the virus to evade innate or adaptive immune system of 
the host. The latent infections ultimately lead to cancer development. (2) They can also act in 
a trans manner to cause deregulation of translation or breakdown of cellular messenger RNAs 
(mRNAs) that are involved in tumor suppression. (3) Interestingly, viruses also initiate 
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transcriptional and/or post-transcriptional dysregulation of host miRNA expression. (4) 
Viruses generate dsRNA molecules or pre-miRNA which compete with host miRNAs and 
affect cellular signaling to transform healthy cell to a tumor phenotype. (5) Viruses also 
produce suppressors of host RNA silencing machinery which bind to host dsRNA and 
interfere with cellular miRNA processor and effector complexes, leading cancer 
development. These recent findings provide new insights into the role of viruses and their 
miRNAs in cancer development.  
 
Figure 7: A. Viral miRNAs have a seed sequence homology to their host miRNA. B. Models of gene targeting 
my viral miRNAs (edited and adapted from the original illustration by Kincaid & Sullivan, 2012) 
A minority of viral miRNAs, called analogs, share seed sequence identity with cellular 
miRNAs. In a previous studies, the miRBase version 18 annotated mature viral miRNAs for 
humans, and chickens, were compared with their respective host miRNAs for identity in 
nucleotides hexamer or heptamer seed sequence (Kincaid and Sullivan 2012). The inner 
circles in the figure 7A represent the number of viral miRNAs with a similarity to host seed 
sequence out of the total viral miRNAs. In the network models of figure 7B, analogous viral 
Introduction 
27 
miRNAs function as host miRNAs through seed sequence similarity, thereby targeting host 
genes. The binding sites for the host miRNA are conserved and allow the viral miRNA to 
target multiple cellular genes. This model of targeting is called host network model. The 
primary target model suggests that some viral miRNAs may evolve to target only one or a set 
of transcripts through new binding sites that are not conserved for host miRNAs. In the 
convergent target model, host and viral miRNAs target the same gene through different 
binding sites. 
Many studies show evidence that viral miRNAs are involved in initiation and progression of 
cancer (Lovat, Valeri et al. 2011). Oncogenic pathways that viruses are known to be 
associated with include cell growth, proliferation, angiogenesis, genetic instability, and 
evasion of apoptosis. Regulation of the MAPK signaling pathway by its miRNAs is an 
essential for KSHV (Qin, Feng et al. 2011). The closely related herpes viruses target PI3K 
pathway to affect cell survival and growth leading to cancer (Vara, Casado et al. 2004, 
Buchkovich, Yu et al. 2008). Both pathways potentially can inhibit KSHV infection 
(Lambert, Shahrier et al. 2007). The PI3K pathway can also enable infected cells to withstand 
viral induced stress (Buchkovich, Maguire et al. 2008). DNA viruses can initiate the MAPK 
pathway by affecting epidermal growth factor receptor (ErbB) signaling pathway resulting in 
tumor growth or differentiation (Tzahar, Moyer et al. 1998). These increasing evidences 
suggest that viral miRNAs may play a role in the oncogenesis. 
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1.4. Representational Difference Analysis (RDA) 
RDA is a subtractive nucleic acid hybridization technique (Lisitsyn, Lisitsyn et al. 1993, 
Lisitsyn, Lisitsina et al. 1995). Generally, in subtractive hybridization techniques, a DNA 
population called the “driver” is hybridized in higher proportions with another DNA 
population called the “tester”. Driver and tester are similar but not identical with each other. 
RDA differed from earlier subtractive hybridization techniques. The genomic complexity 
was significantly reduced in RDA by the use of “representations” of the tester and driver 
DNA populations, obtained through their restriction digestion. This modification is essential 
for RDA to isolate the “target” DNA sequences called the “difference products” (DPs), that 
are present only in the tester but not in the driver.  
 
Figure 8: Basic schematic of representational difference analysis (RDA) procedure. 
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RDA begins with the digestion of the driver and tester DNA with restriction endonuclease 
followed by mixing with high driver to tester ratio. This mixture is then denatured and 
allowed hybridize to form three types of DNA duplexes: homo-hybrids of tester–tester and 
driver–driver, and tester– driver hetero-hybrids. During hybridization, increased driver to 
tester ratio provides a lesser chance for a tester sequence to bind to its tester complement than 
to bind to its driver complement. The unique “difference products” (DPs) present in the 
tester, thus will only hybridize with its complement from the tester DNA population. These 
unique target tester–tester homo-hybrids will then be cloned selectively to sequence and 
identify the DPs DNA information. The higher proportions of driver DNA drive the 
complementary tester sequences out from the pool of tester DNA, thus the name “driver”. 
The DNA population which is used to test against driver with RDA is thus called a “tester”. 
Strauss et al. improved RDA technique by performing multiple rounds of hybridization. This 
modification enriches the DPs present in tester that had been amplified in the previous round 
of hybridization, through second-order kinetics of self-association (Straus and Ausubel 
1990).  
1.4.1. RDA to Study Cancer Genetics 
RDA is used to identify genetic aberrations, in a tumor genome by comparing it with the 
genome of healthy cells (Lisitsyn, Lisitsyn et al. 1993, Lisitsyn, Lisitsina et al. 1995). RDA 
could successfully identify homozygous deletions in tumors from a strong background of 
heterozygous deletions. The BRCA2 and PTEN tumor suppressor genes were identified for 
homozygous deletions found by RDA (Schutte, Dacosta et al. 1995, Li, Yen et al. 1997). The 
position of the DPs in the chromosome-specific yeast artificial chromosome clone arrays was 
provided by the use of genomic RDA (Zeschnigk, Horsthemke et al. 1999). The differentially 
expressing genes between tumor and healthy cells can be analyzed by RDA using cDNA as 
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the starting material instead of DNA (Hubank and Schatz 1994). High-throughput analysis of 
multiple representations is possible by employing cDNA-RDA during microarray 
hybridization (Welford, Gregg et al. 1998). Finally, isolation of sequences that are 
differentially methylated between healthy and tumor cells could also be analyzed using 
methylated CpG island amplification (MCA) coupled with RDA (Toyota, Ho et al. 1999). 
Hence, we used RDA as our experimental approach to isolate the integrated pathogenic viral 
sequences in PDAC patients genomic DNA. This technique successfully provided us the DPs 
which were further analyzed using next generation sequencing (NGS). The results of these 
interesting studies are shown in the following sections.  
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2. RESULTS 
2.1. Representational Difference Analysis (RDA) 
Pancreatic cancer is one of the deadliest diseases with a mortality that is nearly close to the 
incidence. There have been numerous attempts to study genetic perturbations in the cells that 
lead to pancreatic cancer. Majority of these studies employ next generation sequencing 
techniques to identify gene amplifications, gene deletions, single nucleotide polymorphisms, 
mutations, and changes in gene expression. However, rare events such as integration of 
pathogenic virus sequences are, less and rarely studied in pancreatic cancer. Whole genome 
sequencing of tumors employs size selection of genomic libraries and subsequent nucleic 
acid purification prior to sequencing. These are although essential steps, may result in a poor 
identification of rare events like viral integration in the tumor genome. In the present study, 
RDA has significantly addressed this problem by enriching these rare events, or the 
difference products (DPs), by PCR amplification. The enriched DPs are then identified and 
characterized using next generation sequencing technologies. Even though a robust 
technique, RDA is highly sensitive to DNA contamination resulting in false positives. Hence, 
RDA was optimized and performed under sterile laminar hood. 
2.1.1. Optimization of RDA with Pilot Samples 
To establish the protocol for RDA, a small pilot study was conducted. In this study, human 
placental DNA was used as driver. Tester sample was generated by adding bacterial plasmids 
to the driver. The hypothesis was that the RDA between driver and tester should isolate and 
enrich the bacterial plasmid sequences as difference products. Considering the scope of this 
pilot study, TA cloning of the DPs was performed and cloned recombinant colonies were 
single read sequenced instead of using NGS platform.  
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2.1.1.1. Generation of Pilot Representations 
The driver and tester genomic samples were digested with restriction endonuclease. The 
adapters were used to ligate to the digested genomic samples. The adapters were used as the 
primers for PCR to generate the corresponding representations. DNA smear on the gel 
increased in intensity reaching a plateau with increasing cycle number. The plateau was 
observed as a shift of the product toward the larger sizes or to smaller sizes with a decrease in 
quality. Optimal number of cycles (25) for each representation was selected, avoiding this 
plateau phase. The figure below shows that, with increasing PCR amplification cycle 
number, the efficiency as well as sensitivity of amplification decreases. 
 
Figure 9: Representations of driver (human placental DNA) and tester (mixture of human placental DNA and 
bacterial plasmids). A: PCR was performed under sterile laminar hood using the R-Bam-24 adapter as a primer. 
Lanes 1 represents low range DNA ladder; 2, 3, 4 and 5 are driver representations generated by 20, 25, 30 and 
35 cycles of PCR amplification respectively; 6, 7, 8 and 9 are tester representations generated by 20, 25, 30 and 
35 cycles of amplification respectively; 10 and11 are PCR negative controls for 30 and 35 cycles of 
amplification respectively. B: PCR was performed outside sterile laminar hood for negative controls. With the 
increase in amplification cycle, this PCR was positive for DNA. Lane 2, 3, 4 and 5 represent 20, 25, 30 and 35 
amplification cycles respectively. 
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Figure 10: Representations of driver (human placental DNA) and tester (mixture of human placental DNA and 
bacterial plasmids) generated by selecting 25 PCR amplification cycles with R-Bam-24 primer. 
2.1.1.2. First Round of Subtractive Hybridization 
After generation of driver and tester representations by 25 cycles of amplifications each, the 
tester was prepared for subsequent subtractive hybridization to driver. To achieve this, the 
tester representation with R-Bam-24 adapters was subjected to DpnII digestion and new 
adapters J-Bgl-12 and J-Bgl-24 were ligated. The success of this ligation was checked for the 
same 25 cycles of amplification to maintain uniformity of the tester representation. However, 
the adapters from the driver were removed prior hybridization to the processed tester. PCR of 
the first round hybridization mixture with J-Bgl-24 resulted in the amplification of DP1 with 
visible bands on the agarose gel. Different hybridization temperatures were used for the first 
round to optimize the subtraction (data not shown). The least hybridization temperature at 
which non-specific hybridization and amplification does not occur was selected for further 
rounds of subtraction. 
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Figure 11: First round of RDA driver and tester (pilot study) produced DP1 with visible bands of amplification. 
To ensure that the DP1 was amplified with J-Bgl-24, the DP1 was further digested using DpnII. The third lane 
represents the digested DP1. The shift of the bands towards the smaller size confirms the DP1 amplification post 
hybridization. 
2.1.1.3. Enrichment of Difference Products 
The DP1 obtained after the first round of RDA is prepared for subsequent enrichment of 
sequences present only in tester but not in driver. The DP1 was digested with DpnII and new 
adapters, N-Bgl-12 and N-Bgl-24, were ligated. The enrichment of differential sequences is 
possible by using DP1 in place of tester during the second round of hybridization. Using the 
same hybridization temperature optimized during the first round of hybridization, the second 
round of RDA was performed. The DP2 showed enrichment of differential sequences. The 
third round of RDA was performed using DP2 in place of tester against driver. Since the 
complexity of the samples is less, three rounds of RDA were sufficient to isolate unique 
bacterial sequences present in the tester. The highly enriched DP3 was successfully purified 
and cloned using TOPO TA cloning system and the recombinant colonies were single read 
sequenced. 
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Figure 12: Three rounds of RDA. The difference products of each round of subtraction DP1, DP2 and DP3 
were shown beside the tester representation used for the subtraction against driver representation. The PCR 
negative control showed no DNA signal. 
2.1.1.4. Sequence Analysis of Difference Products 
The recombinant colonies obtained by cloning DP3 were selected for single read 
sequenceing. The sequencing data from 96 colonies was used for the analysis. The sequences 
were aligned to human reference genome from NCBI using BLAST algorithm. All sequences 
showed a high similarity to the bacterial cloning vectors confirming that the RDA has 
specifically enriched unique target sequences present only in the tester but not in the driver. 
Since the target sequences were the bacterial plasmid sequences that were added to the 
human placental DNA, the driver, subtractive hybridization isolated and amplified these 
sequences from the driver. Further, there were no similarity hits with human genome 
confirming no false were picked up by the PCR amplifications or nucleic acid purification 
procedures. 
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Figure 13: The sequenced DPs (representative) were used to align to all genomic databases by BLAST. There 
were no matches with human genome. The DPs were identical to the bacterial plasmid sequences shown at the 
bottom panel of the figure. 
2.1.2. RDA between healthy normal tissue DNA and PDAC tissue DNA 
After optimizing the RDA technique with pilot samples, the next step was to use RDA to 
isolate DPs from PDAC patients DNA. A pool of each, healthy controls and PDAC patients 
genomic DNA, were analyzed using this technique. Equal amount of DNA from each set of 
individual healthy samples were added to prepare a normal driver sample. Similarly, tester 
sample was prepared by adding equal amount of DNA from PDAC patients genomic DNA. 
The pooling of samples facilitates two functions; it increases diversity among each set of 
samples being hybridized and increases the coverage of hybridizing-difference products 
between driver and tester. As mentioned earlier in the chapter 1.4, the RDA is highly prone is 
contamination if performed on a daily lab bench environment. Hence, care was taken not to 
contaminate the DNA samples, especially after the restriction digestion. After hybridization 
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between driver and tester, the PCR second order kinetics using the adapters J-Bgl-24 and N-
Bgl-24 as primers pulled difference products from the tester and were enriched during 
subsequent rounds of RDA. 
2.1.2.1. Generation of Healthy and PDAC Representations 
The pooled normal healthy control DNA samples and PDAC DNA samples were digested 
with restriction enzyme and after adapter ligation, a representation of the startup samples 
were generated using R-Bam-24 as primer. As in pilot studies, an optimal number of 
amplification cycles were selected in which, both driver and tester representations look 
similar on an agarose gel. The second lane in the figure below shows no signal of DNA 
contamination in the negative control. 
 
Figure 14: Representations of driver and tester generated from normal healthy and PDAC patients genomic 
DNA. The amount of DNA ladder loaded was indicated in parenthesis to scale the signal intensity in normal and 
cancer representations. 
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2.1.2.2. First Round of Hybridization between Healthy and Tumor Representations 
 
Figure 15: First round of RDA between healthy driver and PDAC tester samples. The amount of DNA ladder 
loaded was indicated in parenthesis to scale the signal intensity in normal and cancer representations. 
The driver was produced in excess by pooling multitude of PCR representations and 
purifying it from the polymerase and free dNTPs. The driver is then prepared for the first 
round of hybridization by digesting the adapters using restriction enzyme. After digestion, 
two clear populations of DNA were seen on the agarose gel (data not shown). The population 
with larger size DNA is the driver alone region and the population with smaller size DNA 
contains the adapters. The driver was extracted from the gel and was hybridized with 
processed tester. The tester was prepared by removing the R-Bam adapters and ligating with 
J-Bgl adapters. The tester population for the first round of hybridization was produced using 
J-Bgl-24 as primer in the subsequent PCR. The tester was also purified of polymerase and 
free dNTPs to ensure optimal hybridization with driver. The difference product obtained after 
the first round RDA lies between the size range of driver and tester representation. The clean 
negative control was crucial at this step as contamination from external sources will be 
picked up easily during hybridization. 
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2.1.2.3. Enrichment of DPs between Healthy and Tumor Representations 
The DP1 obtained in the first round of RDA between healthy and the tumor representation, 
was isolated from the gel to change the adapters and prepare for subsequent rounds of 
hybridization. In addition to the number of rounds of RDA performed in relatively simpler 
pilot study, one more round of RDA was performed between healthy driver and PDAC tester 
as the number and complexity of samples is much higher than the previous pilot study. The 
genomic sequences present only in the PDAC samples were enriched with every round of 
RDA. The DPs were diluted and hybridized against the driver in different ratios before 
hybridization. This step not only increased the competition of similar sequences between 
present in both samples but also amplified the target sequences exponentially. 
 
Figure 16: Four rounds of RDA producing corresponding DPs. The differential genomic sequences between 
driver and tester are enriched with each round of hybridization. 
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2.1.2.4. Bioanalyzer High Sensitivity DNA Assay 
Considering the enrichment factor of differential sequences, DP3 and DP4 are selected to 
further analyze with Bioanalyzer high sensitivity assay. The y-axis in the figure below 
represents florescence units (FU) and the x-axis represents the DNA fragment length, as a 
peak in the area of the graph, in base pairs. The differential target sequences were 
significantly enriched by amplification as can be seen by the increased FU in the DP4 than 
DP3. The peaks with similar number of base pairs appear in both DP3 and DP4 further 
confirming the enrichment of same fragments from previous rounds of RDA. 
 
 
Figure 17: Electropherogram of DP3 and DP4 by analyzing them with high sensitivity DNA assay on 
Bioanalyzer. First and last peaks in the graphs represent loading markers. 
Results 
41 
2.1.2.5. Next Generation Sequencing (NGS) of DPs 
During sequencing, the first four bases of the reads are critical to assign the read clusters by 
the Illumina platform. The DP3, and DP4, were amplified using adapter as primer. This 
resulted in all DNA fragments of the DPs with identical primer nucleotides at the ends. 
Hence it was necessary to randomly digest DPs with ds-DNA fragmentase for 10min before 
sequencing. The DP3, and DP4, were then successfully paired end sequenced.  
 
Figure 18: dsDNA fragmentase digestion of DPs at different time points. 10 min time point was selected since 
it provided lesser degradation of DPs than higher time points. 
 
Figure 19: Extent of sequencing DP3 and DP4 on a single lane. 
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After the quality control, lllumina sequencing of the two samples showed that the level of 
sequence duplication is higher in DP4 than DP3. This further confirms that RDA enriched the 
sequences by amplification without bias. We used two samples on a single lane during 
Illumina paired end sequencing. In a diverse library most sequences will occur few times. A 
low level of duplication may indicate a very high level of coverage of the target sequence, 
but a high level of duplication is more likely to indicate enrichment of relatively few target 
sequences as expected between two samples of same species. 
 
Figure 20: Sequence duplication level of both paired end reads of DP3 and DP4. 
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2.1.2.6. In silico Analysis of the NGS Data from DPs 
The NGS data obtained after sequencing DP3 and DP4 from our core facility is analyzed 
using a modified version of the pipeline previously designed for identifying viral miRNAs in 
PDAC samples (figure 22). The raw data was filtered for the reads without sequencing 
adaptors. The cleaned reads were aligned with reference human genome from NCBI allowing 
few mismatches. As expected more than 90% of the reads aligned with human genome, since 
there would be few nucleotide changes between the driver and tester that would be picked up 
by the RDA owing to its sensitivity. The reads that were not matched with human genome 
were then aligned with Meleagrid herpesvirus-1 (MeHV-1), also called Herpes Virus of 
Turkeys (HVT), genome (we already had strong evidence for the presence of this in PDAC 
by the miRNA content analysis). The reads that are aligned with HVT specific genes are 
further analyzed. 
 
Table 3: Homology of DP3 and DP4 reads with HVT specific genes. HVT075 is representing significantly 
higher number of reads than other HVT specific set of genes. 
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2.2. MicroRNA Sequencing of PDAC 
During the course of the project, a new process became available by which the identification 
of viruses in tumor samples became possible directly, namely by using the sequence analysis 
of the miRNA content of cells. Because of the limited number of molecules, this analysis 
form does not need any selection and amplification step in order to achieve a sufficiently 
enough sensitivity to find viral microRNAs. Upon the identification of viral microRNAs, the 
sequence of the relevant virus could be looked for selectively within the human DNA from 
NGS analysis of RDA. Hence, we sequenced miRNA from eight PDAC patients. We 
sequenced four samples per lane using Illumina MiSeq platform. 
 
Figure 21: Extent of sequencing miRNA from PDAC patients. 
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2.2.1. Digital MicroRNAome Subtraction 
 
Figure 22: Pipeline designed to analyze the miRNA content of PDAC for virus sequences. 
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The miRNA sequencing data from the core facility is analyzed for viral sequences. After 
cleaning the raw data for sequencing adapters, the alignment with human genome showed 
good similarity. This step ensured us that most of the adapters are removed from the data. 
The cleaned reads are now aligned with viral genome to select sequences that have viral 
origin. The reads that matched with viruses could also be present in humans as both species 
coevolved. Hence, the virus matched reads now are aligned with human reference genome. 
This resulted in digital subtraction of the miRNA from human genome. The reads that did not 
align with human genome are uniquely virus. These reads are now aligned with viral 
miRNAs from miRBase.  
2.2.2. Identification of hvt-miR-H14-3p in PDAC 
The miRNA sequencing study showed us many unique viral miRNAs present in PDAC 
patients. However, we identified a top candidate miRNA that is present in higher number of 
reads than other viral miRNAs. This miRNA is from MeHV-1 (also known as HVT). The 
hvt-miR-H14-3p was one of the few miRNAs that also shares sequence homology with two 
human miRNAs, hsa-miR-221-3p and hsa-miR-222-3p. Apart from hvt-miR-H14-3p, we also 
identified few other miRNAs from this virus in the PDAC patients. However, hvt-miR-H13 
was the only other miRNA from this virus that showed considerable number of reads in the 
PDAC in comparison to other miRNAs and was next to the top candidate. 
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Figure 23: Number of reads of all viral miRNAs identified through digital miRNAome subtraction. The graph 
represents average number of miRNA reads from eight PDAC samples after digital subtraction. Hvt-miR-H14-
3p is the top candidate for our study. 
 
Figure 24: Number of reads of different miRNAs from Meleagrid herpesvirus-1 (herpesvirus of turkeys) 
identified through digital miRNAome subtraction. Hvt-miR-H14-3p is having highest number of reads in PDAC 
in comparison to other miRNAs from this virus. It also shares a 100% seed sequence homology with two human 
miRNAs upregulated in PDAC. 
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Hvt-miR- H14-3p H13 H4-3p H15-3p H16-5p H3-3p H18-5p H14-5p 
Ge0288 220 12 NA NA NA NA NA NA 
Ge0382 117 9 1 NA NA NA NA NA 
Ge0395 55 5 NA 1 1 1 NA NA 
Ge0408 54 8 NA NA NA NA NA NA 
Ge0564 104 3 NA NA NA 1 1 NA 
Ge0565 99 1 NA NA NA NA NA NA 
Ge0653 37 6 NA NA NA 1 NA 1 
Ge0870 28 5 NA NA NA NA NA NA 
 
Table 4: The number of different miRNA reads from HVT identified in eight PDAC samples by digital 
miRNAome subtraction.  
2.3. Hvt-miR-H14-3p is Upregulated in PDAC and CP 
As mentioned earlier, hvt-mir-H14-3p resembles two human miRNAs from mir-221 family 
in sequence. There are many studies that provide strong evidence that hsa-miR-221 and 222 
are highly upregulated in PDAC. Since both the miRNAs, from HVT and humans, share 
sequence homology which also extends to their seed sequence, we thought to analyze the 
expression levels of hvt-miR-H14-3p in PDAC and CP in comparison with healthy normal 
controls. We used a human miRNA, RNU44, as a reference gene for normalization of 
expression levels. Hvt-miR-H14-3p was significantly upregulated in tumors and 
inflammation condition in comparison with healthy controls. For the quantitative reverse 
transcription PCR (RT-qPCR), we used miRNA specific stem loop primers that converted 
hvt-miR-H14-3p or RNU44 into a cDNA sequence. The cDNA was further quantified using 
miRNA sequence specific hydrolysis probes by qPCR and digital PCR. Multiple negative 
controls were performed to ensure absence of false positive quantification. 
Results 
49 
2.3.1. Quantitative Real Time PCR Analysis 
The hydrolysis probes for miRNA quantification from Life technologies use a sequence 
specific stem loop primer to convert target miRNA to cDNA from total RNA. Since the copy 
number of the viral miRNA is very low, there was significant standard deviation between 
technical triplicates of qPCR. Further, the quantification cycle (Cq) values were also very 
high for the viral miRNA. However, there was no amplification in multiple negative controls. 
Hence, the amplification observed in viral miRNA sample set was highly specific to the 
genes of interest. The hvt-miR-H14-3p was significantly upregulated in PDAC and CP than 
in healthy normal controls. Further, there was no significant difference in hvt-miR-H14-3p 
relative fold change between PDAC and CP. This suggests that viral miRNA has a role in the 
progression of PDAC from inflammation. 
 
Figure 25: Relative fold change of hvt-miR-H14-3p between healthy normal controls and PDAC, and CP, 
normalized to controls. The numbers in parenthesis represent sample size. Significant upregulation of viral 
miRNA is observed between controls, and PDAC and CP. However, no significant relative fold change is seen 
between PDAC and CP. 
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2.3.2. Digital PCR Analysis 
The viral miRNA is present in very low copy numbers across all samples used in this study. 
This made the quantification of hvt-miR-H14-3p theoretically challenging as the standard 
deviation between technical triplicates was high. Hence a more sensitive and robust 
quantification was employed to compare the viral miRNA at the level of copy number per 
microliter of sample using digital PCR. Two independent digital PCR platforms were used to 
validate the previous qPCR observation. The Bio-Rad platform generated approximately 
14,000 to 18,000 droplets per sample and measured the copy number of target sequence per 
microliter of sample. The RainDance platform generated approximately 4 million droplets 
per sample and quantified the amplification of target gene per droplet. Both platforms 
emphasized the previous observation with qPCR that hvt-miR-H14-3p was significantly 
upregulated in PDAC than in healthy controls. 
 
Figure 26: Copy number variation of viral miRNA between healthy controls and PDAC samples. The number 
of positive and negative events per well are shown on the right side part of the figure. The values in the chart 
area of the left part represent copy numbers of viral miRNA per microliter. The bars represent 95% CI. 
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Figure 28: Relative quantification of hvt-miR-H14-3p between healthy controls and PDAC using RainDance 
digital PCR platform. The observation in qPCR experiments were further validated in this study. Viral miRNA 
showed a significant upregulation in PDAC than in healthy control. 
2.4. Functional Analysis of Hvt-miR-H14-3p in vitro 
The previous section validated the qPCR observation that hvt-miR-H14-3p is significantly 
upregulated in PDAC and CP. The following sections will provide functional analysis of hvt-
miR-H14-3p performed in vitro. Over expression studies were performed in different 
pancreatic cancer cell lines. Messenger RNA target identification was also performed and the 
down regulation of the target upon overexpression of viral miRNA was validated in cell line 
system. These functional studies have strongly suggested the role of hvt-miR-H14-3p in 
invasion and metastasis of PDAC cell lines. To describe briefly, we transfected the cells with 
viral miRNA mimic and negative control. We used these populations of PDAC cell lines to 
study migration, invasion and proliferation simultaneously. The results of each of these 
assays are shown in the following sections. 
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2.4.1. Hvt-miR-H14-3p Overexpression in Metastatic PDAC Cell Lines 
As mentioned in the previous section 1.2.1, the PDAC is a very aggressive disease. Local and 
distant organ metastasis is a significant concern for PDAC patients. Hence, overexpression of 
hvt-miR-H14-3p using second generation mimic systems was performed in order to 
investigate modulation of metastasis by viral miRNA. The figure below convincingly shows 
that overexpressing hvt-miR-H14-3p significantly increases the metastatic PDAC cell 
migration. 
 
Figure 29: Hvt-miR-H14-3p significantly increases migration of metastatic PDAC cell lines. It is shown in this 
figure that CFPAC-1 and Capan-1 migrate respectively around 80 and 60 fold more than their controls. The 
results are represented as means and SD from three independent experiments. 
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2.4.2. Hvt-miR-H14-3p Overexpression in Non-Metastatic PDAC Cell Lines 
In the previous section the overexpression of viral miRNA increased migration of metastatic 
PDAC cell. This observation was crucial as it suggests the role of hvt-miR-H14-3p in 
metastasis. Invasion is a very important phenotypic character of a metastatic cell. Hence to 
follow up on the results on migration, non-metastatic cells were overexpressed with hvt-miR-
H14-3p and their invasion was studied in Matrigel chambers. The non-metastatic primary 
tumor cell lines showed significant increase in invasion in comparison with controls. 
 
Figure 30: This graph shows the percentage of invaded cells upon overexpression with viral miRNA mimic and 
negative control. The invasion of BxPC-3 is more than MIAPaCa-2 upon viral miRNA overexpression. This 
effect is also in correlation with the inherently aggressive nature of the BxPC-3, in that this cell line shows an 
early invasion than MIAPaCa-2. The results are represented as means and SD from three independent 
experiments. 
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2.4.3. Hvt-miR-H14-3p Overexpression and PDAC Cell Proliferation 
The previous sections emphasized that the overexpression of viral miRNA, hvt-miR-H14-3p, 
promoted significant increase in migration and invasion in metastatic and non-metastatic 
PDAC cell lines respectively. To further validate these interesting observations, we 
investigated the proliferation of cells overexpressed with viral miRNA. The migrated and 
invaded cells that were overexpressed with viral miRNA, interestingly, showed no change in 
proliferation. This further validates that the significant increase in migration and invasion of 
viral miRNA overexpressed PDAC cells happened not because of proliferation but due to the 
real phenotype change. 
 
Figure 31: The graphs shown here represent percentage viability of the cells in assay. A: Metastatic cell lines, 
CFPAC-1 and Capan-1 show no change in viable cells. This assay was performed with CellTiter Glo that 
measures ATP. B: Since cells need at least 48hr of culture to express proteins, the second time point was at 48hr 
and in this assay amount of proteins in the cells is measured using SRB. The results are represented as means 
and SD from three independent experiments. 
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Figure 32: As a follow up of the previous experiment, all previous PDAC cell lines, in which increased 
migration and invasion is observed upon viral miRNA overexpression, were used to study proliferation change 
at two farther time points 36hr and 72hr. All of which did not show any significant change in proliferation at 
any time point. The results are represented as means and SD from three independent experiments. 
2.4.4. Hvt-miR-H14-3p Down-regulates p27 Expression 
As mentioned in the earlier sections, the viral miRNA, hvt-miR-H14-3p, shares a great 
degree of sequence homology to hsa-miR-221 and 222 including a 100% identical seed 
sequence, the primary hypothesis was that viral miRNA may target same genes as that of 
human miRNAs. To this end, we over expressed the viral miRNA and performed a Western 
blot to investigate the down regulation of the top candidate mRNA target of human miRNAs, 
p27. This experiment showed that the viral miRNA can target p27 and down regulate the 
levels of P27 in PDAC cell line system. This observation was validated also using a dual 
luciferase expression system. The dual luciferase detection works on the principle that 
miRNA binds to the 3’UTR of targets. If wild type p27 3’UTR binds to viral miRNA, it 
results in down regulation of luciferase signal. If the 3’UTR of p27 is mutated, it can no 
longer bind to the viral miRNA and luciferase signal remains similar to that of the 
constitutively expressing empty vector control. This assay validates the specificity between 
viral miRNA and its target, p27. 
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Figure 33: Western blot for P27 target, and P21 downstream affected protein, shows deregulation after over 
expressing viral miRNA than to negative controls in CFPAC-1 and Capan-1 PDAC cell lines. The result is 
representative of three independent experiments. 
 
 
Figure 34: Dual luciferase assay shows that viral miRNA, hvt-miR-H14-3p, specifically targets 3’UTR of p27 
while leaving mutated p27 3’UTR unaffected. Hvt-miR-H14-3p and negative control were co-transfected with 
the indicated luciferase constructs. Relative luciferase activity is the ratio between firefly luciferase and renilla 
control luciferase, adjusted to 100%. The results are represented as means and SD from three independent 
experiments. 
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2.5. In vivo Validation of hvt-miR-H14-3p Phenotype Using Xenograft Mice 
In vitro culture systems used previously are helpful to investigate specific phenotypes of the 
viral miRNA. However, these systems are simplifications that does not account for the 
complexity or heterogeneity of PDAC as well as the tumor microenvironment.  Hence, in 
vivo studies in nude mice with human PDAC cell lines (xenografts) were performed to 
understand the behavior of PDAC cells overexpressed with viral miRNA. 
2.5.1. Generation of Stable PDAC Cell Lines Expressing hvt-miR-H14-3p 
Lentivirus was used for stable integration of sequence of interest in PDAC cell lines. The 
desired population of lentivirus was produced by cloning hvt-mir-H14 or non-targeting 
scramble control sequence in lentivirus cloning vector. To monitor tumor progression, 
luciferase gene under the control of CMV promoter was also cloned in both populations. 
Using this pair of lentivirus population, two pairs of stable cell lines were produced with 
BxPC-3 and MIAPaCa-2. A mice PDAC cell line, K-8484, was also used for prospective 
studies in orthotopic tumor models. To validate our observations on the role of viral miRNA 
on invasion, we performed the simultaneous invasion and proliferation assays to check if the 
stable cell lines replicate these findings as that of in vitro systems. Similar to our previous 
observations, stable cell lines showed identical data that emphasizes that the significant 
increase in invasion of PDAC cells, overexpressed with viral miRNA, however, without 
significant change in proliferation. 
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Figure 35: Stable cell lines show significant increase in invasion over time post transduction. Both non-
metastatic cell lines invade significantly more than their controls. This graph shows percentage of invasion 
normalized to negative controls at 100%. The results are represented as means and SD from three independent 
experiments. 
 
Figure 36: Stable cell lines show no significant change in proliferation over time post transduction. This graph 
shows percentage of viable cells normalized to negative controls at 100%. The results are represented as means 
and SD from three independent experiments. 
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2.5.2. Tumor Progression in Mice Injected with hvt-miR-H14-3p Stable Cells 
The stable cell lines of BxPC-3 and MIAPaCa-2 expressing hvt-mir-H14 or non-targeting 
scramble control sequence were subcutaneously injected into the right flank of the mice on 
the abdomen in four different respective groups. Bioluminescence (BLI) and tumor volumes 
were measured after the tumor has reached a reached a significant size in mice. With our 
preliminary data, the cohort of mice with BxPC-3 stable cell lines expressing hvt-mir-H14 
showed a significant increase in tumor progression within 3 weeks in comparison with its 
scramble control cohort also effecting survival of mice. 
 
Figure 37: The group of mice expressing viral miRNA, hvt-miR-H14-3p, showed significant increase in tumor 
progression in comparison with the group of scramble control mice. A: The BLI measurements taken by 
anesthetizing mice and injecting them with luciferin. The luminescence corresponds to tumor progression. B: 
The bioluminescence is quantified in terms of total photons in the region of interest (ROI). The graph clearly 
shows that the viral miRNA significantly increases the tumor progression in mice expressing viral miRNA in 
their tumors in comparison with scramble controls. C: Post transplanting transduced cells, mice survival 
significantly reduced with increase in tumor progression in viral miRNA cohort than in control group.  
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3. DISCUSSION 
In order to understand the importance of the findings in this project, it is essential to discuss 
the relation between genomic integration of viruses and carcinogenesis. In the following 
sections, a brief review of carcinogenic mechanisms mediated by sequence integration of 
three major tumor viruses, HBV, HPV, and EBV, are discussed to declutter various pathways 
that are affected, or could be involved in, tumor initiation or progression. 
3.1. Integration of Pathogenic Virus Sequences in Cancer Genome 
Various sequencing platforms have proved effective for discovering novel viruses and virus–
tumor associations; however, these methods are at infancy to be helpful for comprehensive 
patient cohorts. Gene fusion events that happen recurrently include HPV in RAD51B, ERBB2 
and in the 13q22.1 intergenic region harboring the LINC00393 lncRNA. Coevolution of host 
and viral genes provide important information about papillomavirus oncogenes function.  
Integrations are usually associated with altered gene expression (Peter, Stransky et al. 2010). 
Viral integration is usually the result of induction of local genomic instability. However, 
integration could also happen by pre-existing instability. Analysis of host transcriptome 
aberrations caused by oncoproteins can progress the identification and prioritization of 
oncogenes and pathways (Rozenblatt-Rosen, Deo et al. 2012). Abundant enrichment of low 
copy viral integration events from PDAC by RDA here enabled us to identify the virus and 
analyze host cell function in relation to the viral infection and viral gene expression at a 
previously undetectable scale and level of detail. 
Circular viral DNA or tandem arranged genomes could also act as intermediates for 
integration. These integrations involve preferential activation of the cohesive end region 
analogous with retrovirus genome integration (Varmus and Swanstrom 1985). Virus DNA 
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can also integrate randomly along cancer genome, but random integration follows 
preferential loss of DNA in the cohesive end region. Tsurimoto et al. in 1987 proposed that 
three tandem arranged complete HBV genomes can be spread in integrated form in a 
hepatoblastoma cell lines (Tsurimoto, Fujiyama et al. 1987). 
Viruses that are involved in carcinogenesis include several DNA viruses such as KSHV, 
MCV, EBV, HPV, HBV and SV40, and RNA viruses like HTLV-1 and, HCV. Incidence of 
cancer is also associated with integration of the viral genome for several oncogenic viruses, 
including HBV, HPV and MCV. Additionally, evidence is not clear that integration of EBV 
is a mechanism for carcinogenesis. The incidence of virus integration depends on the amount 
of DNA damage; because integration requires double strand breaks in both the host and virus 
DNA (Pett and Coleman 2007). Also, one of the major causes of DNA damage is oxidative 
stress, which can be triggered by viruses and enhanced by exogenous factors. 
3.1.1. Strategies for Virus Sequence Integration 
3.1.1.1. Hepatitis B Virus (HBV) 
Hepatocellular carcinoma (HCC) is the one of the lethal form of cancer leading third in cause 
of cancer deaths worldwide (El-Serag and Rudolph 2007), and more than 70% of HCC is due 
to either HBV or HCV infection (Perz, Armstrong et al. 2006). HBV is a partially double-
stranded DNA hepadnavirus with majority of retroviral features. The risk of HCC increases 5 
to 15 fold in chronic HBV carriers compared with the healthy virus free individuals (El-Serag 
and Rudolph 2007), and there are evidences that show the integration of the HBV genome 
into the cellular genome is present in over 85%–90% of HBV-related HCCs. However, non-
tumor tissues of patients with chronic HBV infections also carry the integrated form of HBV 
in their genome. Persistent HBV infection leads to integration of the HBV genome into 
hepatocytes thus leading to HCC (Brechot, Pourcel et al. 1980, Shafritz, Shouval et al. 1981). 
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HBV integration causes elevated expression of several cellular oncogenes, such as TERT, 
mixed-lineage leukemia 4 (MLL4). MLL4 is a part of the ASC-2 complex implicated in the 
p53 tumor suppressor pathway (Lee, Kim et al. 2009) and CCNE1 (encoding cyclin E1) 
(Sung, Zheng et al. 2012). HBV integration is further associated with early onset of HCC 
(Sung, Zheng et al. 2012). It was also show in previous studies that the integrated HBV 
sequences that encode HBx and/or truncated envelope pre-S2/S proteins are found in 
majority of HCC cases (Tsai and Chung 2010). As mentioned in the previous section, genetic 
instability would result, if events such as integration of the HBx sequence into host DNA 
happen in HCC. Mechanisms including the inactivation of the UV-damage DNA binding 
protein resulting in aberrant nucleotide excision repair, inactivation of p53-dependent 
apoptosis, repression of p53-mediated gene transcription (Lee and Rho 2000) and, cell cycle 
regulation, DNA repair and tumor suppression (Kremsdorf, Soussan et al. 2006). HBx also 
trans-activates several signaling pathways connected to carcinogenesis, including those 
mediated by protein kinase C, JAK/STAT and PI3K (Feitelson and Lee 2007, Feitelson, Reis 
et al. 2009). Further, HBx also promotes carcinogenesis by upregulating TGF-β expression in 
HCC tissue (Yoo, Ueda et al. 1996). TGF-β inhibits hepatocyte proliferation during liver 
regeneration (Nakamura, Tomita et al. 1985, Braun, Mead et al. 1988, Fausto and Mead 
1989). During liver cirrhosis, TGF-β also stimulates extracellular matrix protein production 
by hepatocytes (Czaja, Weiner et al. 1989, Nakatsukasa, Nagy et al. 1990). A truncated 
envelope pre-S2/S protein that is frequently found in HCC samples originates from the 
deletion of the preS2 region of the S2/S protein during HBV integration (Tai, Suk et al. 
2002). Pre-S2/S truncated product by trans-activates several cellular genes such as c-myc, c-
fos and c-Ha-ras promoting malignant transformation (Schluter, Meyer et al. 1994, Luber, 
Arnold et al. 1996). Interestingly, the pre-S mutant large surface antigens are present in the 
endoplasmic reticulum. This strategy evades detection by the host immune system. This 
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protein can also trigger ER stress that induces oxidative DNA damage and thus promotes 
genomic instability (Wang, Huang et al. 2006). The cell cycle progression and proliferation 
of hepatocytes is induced by the pre-S, by upregulating COX-2 and cyclin A(Wang, Huang et 
al. 2006). 
The integration rate of HBV DNA into the host genome is significantly increased in the 
presence of DSBs (Bill and Summers 2004). Integration of HBV into the human genome 
occurs at susceptible sites in the genome that are involved in regulation of cell signaling, 
proliferation and viability (Murakami, Saigo et al. 2005). Common targets of HBV 
integration include human cyclin A2 (Wang, Zindy et al. 1992), the PDGF receptor, calcium 
signaling-related genes, mixed lineage leukemia encoding genes, 60S ribosomal protein 
genes (Murakami, Saigo et al. 2005), human telomerase reverse transcriptase (hTERT) 
(Horikawa and Barrett 2001) and the retinoic acid receptor β (Yaginuma, Kobayashi et al. 
1987). The next-generation sequencing data allowed not only to determine the integration 
sites, but also to specify DNA damage, and to identify the mutations that contribute to 
carcinogenesis (Barzon, Lavezzo et al. 2011, Li and Mao 2013). These studies have shown 
that HBV integrates into TERT, MLL4, CCNE1 and ANGPT1 (encoding angiopoietin 1) 
(Fujimoto, Totoki et al. 2012, Jiang, Jhunjhunwala et al. 2012, Sung, Zheng et al. 2012). 
They also identified mutations in CTNNB1 (encoding β-catenin), IRF2 (encoding interferon 
regulatory factor 2), TP53, ARID2 (subunit of the polybromo- and BRG1-associated factor 
chromatin remodeling complex (Yan, Cui et al. 2005), a tumor suppressor gene) (Li, Zhao et 
al. 2011) and ARID1A (encoding a component of the SWI/SNF chromatin remodeling 
complex) (Li, Zhao et al. 2011, Guichard, Amaddeo et al. 2012, Huang, Deng et al. 2012). 
ARID2 mutations are correlated with HCV-associated HCC (Li, Zhao et al. 2011), ARID1A 
is also involved in HCC invasion and metastasis (Huang, Deng et al. 2012). IRF2 mutations 
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result in hyperploidy and high genomic instability (Guichard, Amaddeo et al. 2012). TP53 
silencing mutations result in an deregulated p53 pathway (Guichard, Amaddeo et al. 2012).  
Altogether, the process of HBV integration induces significant genetic aberrations, including 
chromosomal deletions, translocations, transcripts fusion, DNA duplication, and finally 
genomic instability (Guerrero and Roberts 2005, Feitelson and Lee 2007). All these 
alterations lead to overexpression of oncogenes, deregulation of tumor suppressor genes and 
aberrant microRNA profile (Feitelson and Lee 2007). 
3.1.1.2. Human Papillomaviruses (HPVs) 
HPV is circular, double-stranded DNA virus. There are more than 100 different genotypes of 
HPV (Calleja-Macias, Kalantari et al. 2005). Few of them are classified as either high risk or 
low risk casual agents for cervical cancer (Parkin and Bray 2006, Stewart and Wild 2014). 
High-risk HPVs integrate into the host genome causing cancer lesions (Arends, Buckley et al. 
1998, Scheurer, Tortolero-Luna et al. 2005). More than 90% of cancerous lesions in the 
uterine cervix are HPV DNA positive (zur Hausen 1991, Clifford, Rana et al. 2005). 90% of 
all cervical cancer cases are attributable to HPV16, HPV18, HPV31 and HPV33. Majority of 
invasive cancers contain integrated HPV-16. This suggests that integration is an important for 
invasion and tumor progression (Hopman, Smedts et al. 2004, Guo, Sneige et al. 2007). The 
generation of reactive oxygen species and reactive nitrogen species during lesion formation, 
creates double stranded breaks in both the viral and host DNA. This allows HPV to integrate 
into the human genome. HPV integration sites are distributed randomly throughout the host 
genome, without a single region predominating (Wentzensen, Vinokurova et al. 2004). High-
risk HPV integration occurs within or adjacent to host oncogenes (Wentzensen, Ridder et al. 
2002, Ferber, Thorland et al. 2003, Thorland, Myers et al. 2003, Wentzensen, Vinokurova et 
al. 2004). This integration enables E6 and E7 (oncogenes) overexpression, which promotes 
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malignant transformation. HPV-16 integration disrupts E2 gene since the E2 ORF is a 
preferential site of integration. This results in significant increase of E6 and E7 oncoproteins 
expression levels as E2 viral regulatory protein losses control over negative feedback (von 
Knebel Doeberitz 2002, Pett and Coleman 2007). However, Low-risk types are usually 
present as episomal fraction. The levels of E6 and E7 oncogene expression are low in 
episomal HPV16. Further, during latency, transcriptional activity of integrated HPV-16 DNA 
is down regulated by E2 proteins from the episomal form (Bechtold, Beard et al. 2003, 
Herdman, Pett et al. 2006, Pett, Herdman et al. 2006, Pett and Coleman 2007, Hafner, 
Driesch et al. 2008). The cell proliferation, anti-apoptotic effects, and inflammation, 
combined with low-level expression of the E6 and E7 oncogenes encoded by the episomal 
HPV, contribute to tumor lesion progression (Williams, Filippova et al. 2011).  
E6 and E7 expression affects a number of signal transduction pathways. E6 is involved in the 
rapid degradation of p53 and activates hTERT, while E7 inactivates pRB (zur Hausen 2000). 
Further, E6 binds to and inhibits interferon regulatory factor-3 transcriptional activity. This 
strategy helps HPV to evade antiviral response from host immune system (Ronco, Karpova et 
al. 1998). E7 mediate the activation of cyclin E and cyclin A required for malignant 
transformation (Zerfass, Schulze et al. 1995). Interactions between the E6 and E7 proteins 
also leads to cellular immortalization (Band, Zajchowski et al. 1990, Munger and Phelps 
1993).  
Altogether, the elevated expression of oncoproteins from integrated forms of HPV 
deregulates cellular proliferation, blocks apoptosis and increases genomic instability, all of 
which contribute to cellular transformation. 
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3.1.1.3. Epstein-Barr Virus (EBV) 
EBV is a double-stranded DNA herpesvirus that is majorly associated with Burkitt’s 
lymphoma (Epstein, Achong et al. 1964). Burkitt’s lymphoma has three clinical variants 
namely, the endemic, sporadic, and immunodeficiency associated variants. EBV is detected 
in majority of endemic Burkitt’s lymphoma (zur Hausen, Schulte-Holthausen et al. 1970). In 
contrast, EBV is rarely detected in the sporadic Burkitt’s lymphoma (Xing and Kieff 2007). 
EBV-Burkitt’s lymphoma is common in individuals with low levels of efficient T-cells (Kieff 
and Rickinson 2007). 
Chromosomal translocations are common in Burkitt’s lymphoma. These translocations place 
MYC oncogene under the control of the Ig heavy chain or one of the light-chain loci inducing 
MYC deregulation. This leads to the Burkitt’s lymphoma (Polack, Hortnagel et al. 1996, 
Kovalchuk, Qi et al. 2000, Li, Van Calcar et al. 2003). EBV also displays transformative 
abilities. EBV induces B-cell transformation by dergulating cellular gene transcription and 
upregulating cell-signaling pathways (Young and Rickinson 2004). Like HPV low-risk 
strains, EBV usually persists in an episomal state with copies of circular DNA. In addition, 
EBV integration into host genome is rare and does not contribute to Burkitt’s lymphoma. 
However, in several Burkitt’s lymphoma cell lines, such as IB4, BL-36, BL-60 and BL-137 
EBV integration has been evidenced (Matsuo, Heller et al. 1984, Delecluse, Bartnizke et al. 
1993, Popescu, Chen et al. 1993, Wolf, Pawlita et al. 1993, Jox, Rohen et al. 1997). 
Integrated, episomal and linear copies of EBV DNA can coexist in Burkitt’s lymphoma cells 
(Delecluse, Bartnizke et al. 1993). EBV integration in the host genome induces chromatin 
instability in the host cell genome (Jox, Rohen et al. 1997). This genome instability can in 
turn result in the loss of host tumor suppressor genes, such as BACH2 promoting 
carcinogenesis (Takakuwa, Luo et al. 2004). 
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3.2. Integration of Herpes Virus of Turkeys sequences in PDAC Genome 
NGS-based methods, as the one employed in this thesis work, provide a very efficient 
method to map viral integration sites. Half of the mapped HPV16 integration sites directly 
target human cellular genes (Xu, Chotewutmontri et al. 2013). These studies suggest that, in 
some cancers, the insertional mutagenesis of the host genome plays a crucial role in 
tumorigenesis (Pett and Coleman 2007). However, many studies using NGS focused on 
identifying viral genotype and viral load, rather than on identifying integration sites 
(Conway, Chalkley et al. 2012, Meiring, Salimo et al. 2012). Hence our study presents a 
unique scenario of identifying both, the virus – MeSHV-1 or HVT and its integration sites, in 
pancreatic cancer. 
HVT was first isolated in 1969 and is antigenically related to Marek’s disease virus (MDV) 
(Gibbs, Nazerian et al. 1984). HVT is ubiquitous and non-pathogenic for chickens. Hence, 
HVT is routinely used in the poultry industry to vaccinate chickens against MDV. HVT 
infections are persistent in chickens hence provide long-lasting immunity (Purchase, Okazaki 
et al. 1972, Witter and Solomon 1972, Lee 1980, Fabricant, Calnek et al. 1982, Calnek and 
Witter 1991). The epidemiological features of natural HVT infection in turkeys include, early 
appearance of infection, rapid spread throughout the flock and as mentioned earlier, its 
persistence. Data from previous studies indicate that both HVT and the virulent MDV share 
many epidemiological features (Witter and Solomon 1971). These studies suggested that the 
rapid spread of HVT infection within turkey flocks is by horizontal transmission mediated by 
environmental factors such as air and dirty isolation cages acting as natural reservoirs for the 
virus. HVT can also transmit similar to MDV, in that, it can form into enveloped viral 
particles on skin of turkey flocks (Witter and Solomon 1971). Hence, the natural process in 
chickens such as shedding can transmit HVT. However, pathogenicity of HVT with regard to 
tumor induction is not reported to date, at least in humans. 
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4. CONCLUSION 
In the present study, we observed the first clues on HVT sequence integration events in 
PDAC and further validation is being carried out on these findings. However, we identified 
multiple miRNAs from HVT through NGS analysis in PDAC patients. One of the miRNAs, 
hvt-miR-H14-3p, is also shown to be upregulated both, in PDAC and CP patients by 
quantitative real time PCR. Functional analysis of HVT miRNA later showed that it promotes 
tumor invasion and progression both, in vitro in PDAC cell lines, and in vivo in nude mice. 
Interestingly, this effect of invasion and migration on PDAC cell lines is accompanied by 
without significant change in proliferation. These observations suggest a plausible role of 
HVT in the aggressive nature of pancreatic cancer.  
Hence this study represents the first documented evidence of HVT pathogenicity with regard 
to pancreatic cancer in humans. Furthermore, subtractive hybridization followed by NGS 
analysis showed that a putative uncharacterized protein highly specific to HVT is involved in 
high number of integration events in PDAC genome (table 4). Further analysis of this region 
showed that the DP3 and DP4 reads were highly specific to this region across the databases. 
These findings suggest a strong role of the HVT075 gene into PDAC genome integration and 
tumor progression. According to our present working hypothesis, this gene might have 
similar implications as that of BARF1 from EBV or Pre-S2/S truncated protein of HBV or 
E6/E7 of HPV. We are also working to identify very specific cellular mRNA targets for the 
HVT miRNA. We have already showed that hvt-miR-H-14-3p, like its homologous human 
miRNA has-miR-221, targets cellular p27. Thus the knowledge of HVT mediated 
carcinogenesis, and the network of pathways involved in the transition from initial infection 
to the pancreatic cancer provide clues on prophylactic and therapeutic strategies, which may 
ultimately reduce the risk of HVT-mediated PDAC. 
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5. MATERIALS AND METHODS 
5.1. Materials 
Equipment 
Name Manufacturer 
Centrifuge 5415D  Eppendorf, Germany 
Centrifuge 5810R  Eppendorf, Germany 
NanoDrop ND 1000 Spectrophotometer  Thermo Scientific, USA 
PCR Thermocycler PTC200 MJ Research  BioRad, USA 
pH-Meter MP 230 Mettler Toledo  Mettler Toledo, Germany 
 
Lab ware 
Name  Manufacturer 
96-well culture plate  Greiner Bio-One, Germany 
Cell culture microplate,96 well, F-bottom Greiner Bio-One, Germany 
Cell culture Petri dishes 96 x 20 mm  Corning Life Science, USA 
Eppendorf Safe-Lock tubes 1.5 mL and 2 mL  Eppendorf, Germany 
Falcon 15 mL and 50 mL  Greiner Bio-One, Germany 
Latex gloves  Latex, Blossom Mexpo, USA 
Lazy-L-Spreaders  Sigma-Aldrich, USA 
Microtiter cover film  Nunc, Germany 
Nitril gloves Nitril, Microflex, Austria 
Parafilm PM 996 Fisher Scientific, USA 
Microplates 96 and 384 well for PCR Greiner Bio-One, Germany 
Sterile filter 500 mL Nalgene, USA 
 
Chemicals 
Name  Manufacturer 
1,2-Bis(dimethylamino)ethane (TEMED)  Roth, Germany 
2-Ethanesulfonic acid (HEPES)  Roth, Germany 
Acrylamide/Bisacrylamide  Roth, Germany 
Agar  Roth, Germany 
Agarose  Invitrogen, USA 
Ammoniumpersulfate (APS)  Roth, Germany 
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Ampicillin (sodium salt)  Genaxxon, Germany 
BSA (bovine serum albumin)  Sigma-Aldrich, Germany 
Disodium phosphate (Na2HPO4)  Roth, Germany 
DL-Dithiothreitol (DTT) Sigma-Aldrich, Germany 
Ethanol, absolute  Sigma-Aldrich, Germany 
Ethidium bromide  AppliChem, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich, Germany 
O’ GeneRulerTM 100 bp DNA marker MBI  Fermentas, St. Leon-Rot 
Glycerol  Sigma-Aldrich, Germany 
Imidazole  Roth, Germany 
Isopropyl-β-D-thiogalactopyranoside (IPTG)  Roth, Germany 
Kanamycin  Genaxxon, Germany 
Methanol  VWR, Germany 
Monosodium phosphate (NaH2PO4)  Roth, Germany 
Oligonucleotides  Biomers, Germany 
Oligonucleotides  Sigma-Aldrich, Germany 
Protein-Marker: Broad Range  NEB, Germany 
QIAGEN's 10xPCR buffer  Qiagen, Germany 
Sodium chloride (NaCl)  Sigma-Aldrich, Germany 
Taq DNA Polymerase  Qiagen, Germany 
Tris-base  Sigma-Aldrich, Germany 
Tris-HCl  Sigma-Aldrich, Germany 
Triton X 100  Gerbu, Germany 
TRIzol® Reagent  Invitrogen, Germany 
Tryptone/Peptone  Roth, Karlsruhe, Germany 
Tween 20  Sigma-Aldrich, Germany 
Yeast extract  Gerbu Biotechnik, Germany 
 
Kits 
Name  Manufacturer 
Qiagen QIAprep Spin Miniprep Kit  Qiagen, Germany 
Qiagen QIAquick PCR Purification Kit  Qiagen, Germany 
Dual-Luciferase® Reporter Assay 
System 
Promega, Germany 
5 Prime PCR Purification Kit 5 Prime, Germany 
PureLink PCR purification Kit Life Technologies 
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Buffers and media 
Name  Composition 
0.5 M EDTA pH 8.0  Dissolve 186.1 g Na2EDTA∙2H2O in 800 mL 
dH2O.adjust pH to 8.0 with NaOH (~20 g of 
NaOH pellets). EDTA will dissolve at pH 8.0. 
Adjust volume to 1 liter with dH2O. Sterilize by 
autoclaving and store at room temperature. 
1 M Ethanolamine  60.5 ml ethanolamine in 1000 mL 
1 M NaH2PO4 (monobasic)  138 g NaH2PO4∙H2O in sufficient H2O to make 
a final volume of 1 L 
1 M Tris-HCl pH 6–8  12.1 g Tris base in 100 mL H2O, adjust pH with 
concentrated HCl 
10 M NaOH  40 g NaOH in 100 ml H2O 
1M HEPES-NaOH pH 7.5  Dissolve 238.3 g HEPES in 1 L H2O. Use 
NaOH pellets to adjust pH to 7.5. Start with 
about 5.5 g NaOH pellets 
1M Na2HPO4 (dibasic)  142 g of Na2HPO4 in sufficient H2O to make 
final volume 1 L 
6xGel-loading buffer  25 mg bromophenol blue and 4 g sucrose, make 
up volume to 10 mL with dH2O, store at 4°C 
Ethidium bromide solution  0.5 μg/mL final concentration 
Laemmli  buffer 30.1 g Tris base, 144.2 g glycine, 
50 mL SDS (20%), add 1 L dH2O 
LB Agar  LB-medium + 1.5% (w/v) agar 
LB Medium (1 Liter)  
 
10 g Tryptone/Pepton, 5 g yeast extract, 
10 g NaCl, pH 7.2 
PBS 10x (1 Liter)  
 
80 g NaCl, 2 g KCl, 26.8 g Na2HPO4, 2.4 g 
KH2PO4, pH 7.4 
PBST 1x (1 Liter)  1x PBS/0.05% Tween-20 
TBS 10x (1 Liter)  50 mM Tris, 150 mM NaCl with HCl, pH 7.5 
TBST 1x TBS/0.05% Tween-20 
Transfer buffer 150 mM glycine, 25 mM Tris base, 20% ethanol 
3x EE hybridization buffer 30 mM EPPS (pH 8.0), 3 mM EDTA 
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5.2. Methods 
5.2.1. Representational Difference Analysis 
The protocol for RDA was adapted from (Frohme and Hoheisel 2006). An overview of the 
procedure was presented in a schematic in the figure 38. Pool of 10 genomic samples from 
normal healthy individuals is use as a driver and a pool of 10 genomic DNA samples from 
PDAC patients is used as tester. Briefly, DNA from the two pools was digested with DpnII 
and then ligated with R-Bam-12 and R-Bam-24 oligomers for PCR-amplification separately. 
To establish a similar library of driver and tester representations, many PCRs with different 
number of cycles ranging from 20 to 30 cycles of amplification were performed using R-
Bam-24 as primer. 25 cycles of amplification generated a uniform representation for driver 
and tester. As the driver is used in relatively higher amounts than the tester, 96 PCRs of 
driver and 8 PCRs of tester were done with 25 cycles of amplification. All the reactions of 
driver and tester were pooled separately and DNA was isolated. Both the driver and tester 
DNA were digested again by DpnII and purified to remove the R-oligomers. New J-Bgl-12 
and J-Bgl-24 oligomers were ligated to tester DNA alone. Now, driver and tester were mixed 
in a 100:1 ratio and denatured for a first round of subtractive hybridization. A difference 
product (DP1) was obtained and prepared for a second round of RDA (driver:tester = 800:1) 
by changing the J-adaptors to N-Bgl-12 and N-Bgl-24 oligomers. The DP2 so obtained was 
again prepared for a third round of RDA (driver:tester = 400,000:1) to achieve DP3. 
Similarly, DP3 was prepared for fourth round of RDA with a driver:tester ratio 8,000,000:1. 
The difference products, DP3 and DP4 were digested with dsDNA fragmentase and paired 
end sequenced on Illumina platform. For pilot studies with human placental DNA and 
bacterial plasmids, the DP3 was cut out from the gel; the DNA was extracted and cloned into 
vectors using TOPO TA cloning system. Recombinant clones were selected for single-read 
sequencing. 
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Figure 38: Schematic of the representation of RDA procedure. 
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5.2.2. DPs and MicroRNA Sequencing 
The DPs of RDA, and total RNA samples from PDAC patients, were submitted to our core 
facility at German Cancer Research Center (DKFZ), Heidelberg. The samples have are 
quality checked by the core facility using Bioanalyzer high sensitivity assays. DPs were 
sequenced using Illumina paired-end sequencing platform. The miRNAs were sequenced 
using Illumina MiSeq platform. The quality control data is provided in the digital 
supplementary information. 
5.2.3. NGS Analysis of Sequencing Data 
The data from DPs was cleaned to remove sequencing adapters. The filtered reads were 
aligned with human reference genome from NCBI RefSeq GRCh37. The sequences that were 
not aligned with human genome were selected and aligned with MeHV-1 complete genome 
from NCBI. The paired end sequencing reads that matched with the MeHV-1 genome were 
selected and sorted according to the p value, percentage identity, overlap length, mismatches, 
and gaps. The regions of the MeHV-1 where there are majority read alignments were 
compiled to map the reads against virus genome. The MeHV-1 specific set of genes were 
selected and checked for alignment with the reads from DPs. 
For miRNAs analysis, the MiSeq reads from the PDAC patient samples were first cleaned to 
remove sequencing adapters using sRNA mapper by turning of the mapping function. The 
success of adapter removal was checked by aligning the reads with human genome from 
NCBI RefSeq database. Reads with an alignment percentage greater than 90% are considered 
to be filtered from adapters. The clean reads are then aligned with viral genome from NCBI 
RefSeq Viral (version: 14.09.2013) database allowing 1 mismatch and 0 gaps. The reads that 
are aligned with viral genome are selected and filtered for human sequences by aligning them 
with human genome from NCBI RefSeq human genome database. The reads that did not 
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align with human database but aligned with viral database aligned earlier were considered to 
be uniquely viral in origin or virus only sequences. These reads are then aligned with all 
available miRNAs from miRBase 21. The top candidates were selected and compiled for 
further analysis. 
5.2.4. Hvt-miR-H14-3p Expression Analysis 
5.2.4.1. Quantitative Real Time PCR 
The RNA from healthy normal, PDAC, and CP patients was isolated using Trizol reagent 
from Sigma. 10ng of RNA from the samples is reverse transcribed to miRNA specific cDNA 
using miRVana assay system following manufacturers’ protocol from Life technologies. The 
cDNA from all biological groups is now quantitated using hydrolysis probes from the assay 
system. RNU44 was used as reference gene to normalize expression of viral miRNA across 
the samples. 
5.2.4.2. Digital PCR 
The cDNA prepared as described in the previous section was also used for digital PCR with 
two independent platforms.  
Bio-Rad QX100 digital PCR platform used the same qPCR reaction setup from life 
technologies and generated approximately 14,000 to 18,000 oil droplets per reaction. The 
quantitative data generated from each droplet per reaction was analyzed using QuantaSoft 
software to determine copy number of gene of interest from the samples. 
RainDance platform also used the same qPCR reaction setup from life technologies but 
generated approximately 4 million oil droplets per reaction. The quantitative data generated 
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from each droplet per reaction was analyzed using RainDance Analyst software to determine 
relative fold change of gene expression across samples. 
5.2.5. In vitro Experiments 
5.2.5.1. Cell Culture 
Different types of PDAC cell lines were cultured. MIAPaCa-2, Capan-1 and PANC-1 were 
cultured in DMEM containing 10% FBS, 1% antibiotic. MIAPaCa-2 was further 
supplemented with 1% pyruvate. BxPC-3, CFPAC-1 and Capan-2 were grown in RPMI, 
IMDM and McCoy medium respectively, each supplemented with 10% FBS, 1% antibiotic . 
All these cell lines were passaged 1:5 every fourth day. All the cells were cultured by 
incubation in a dedicated chamber with 5% CO2 supply at 37
o
C temperature. The cells were 
regularly tested for mycoplasma contamination and also genotyped for authenticity. 
5.2.5.2. Transfection of Cells 
RNA transfections were carried out in 6-well plates using siPORTTM NeoFXTM (Ambion) 
reagent and Lipofectamine 2000 (Invitrogrn). Reverse transfection by means of siPORT
TM
 
NeoFX
TM
 involves simultaneous transfecting and plating of cells. siPORTTM NeoFXTM 
transfection agent and the RNA molecules are mixed and distributed on the culture plates 
over which the cells are overlaid. The final transfection volume in a 6-well plate is 2.5 ml of 
medium containing 2 x 10
5
 cells per well. As the transfection complexes are stable in 
presence of serum, no change of medium or other precautionary measures taken in case of 
Lipofectamine 2000 transfection method are needed. The final concentration of the RNA 
molecules transfected was 10µM. After this procedure, the plates were maintained in 
incubation chamber at 37ºC and 5% CO2. 
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5.2.5.3. Migration Assays 
HTS Transwell inserts were used by adding serum rich chemoattractant medium 235µL/well 
to the 96 well plates, followed by adding the Transwell inserts and lastly adding the 75µL 
serum free medium with 10,000 cells overexpressing viral miRNA or non-targeting negative 
control, to the inside compartment per well. An initial equilibrium period was used to 
improve cell attachment by adding medium to the 96 well plate wells and then to the 
Transwell inserts. The plate was then incubated for at least one hour at the same temperature 
that was used to grow the cells. The cells are then added in the fresh medium to the Transwell 
insert and returned to the incubation chamber. To count the number of migrated cells, both 
the well plate and Transwell inserts were rinsed with PBS. Trypsin was then added in the 
plate wells and incubated to dissociate the migrated cells in to the well plate. The detached 
cells were then measured by CellTiter-Glo Luminescent Cell Viability Assay in 8 technical 
replicates for each condition in 3 independent experiments. 
5.2.5.4. Invasion Assays 
BioCoat Matrigel TM invasion plates were used for the assay to check invasion of PDAC 
cells after overexpressing viral miRNA or non-targeting negative control. 0.1 Million cells 
per well were seeded in the inserts with a serum free medium. BD falcon TC companion 
plate was filled with 500µL of the serum rich medium. The serum rich medium in the plate 
wells acts as chemoattractant. 24hr post incubation, the Matrigel chambers were rinsed with 
PBS, placed in the companion plate wells with accutase and incubated for 10 min. This 
procedure allowed the invaded cells on the lower side of the Matrigel to detach and these 
detached cells were measured by CellTiter-Glo luminescent Cell Viability Assay in 8 
technical replicates for each condition in 3 independent experiments.
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5.2.5.5. Proliferation Assays 
The proliferation assay was performed with PDAC cells overexpressing viral miRNA or non-
targeting negative control. 10,000 cells per well were seeded in 96 well transparent and 
opaque plates. The cells seeded in transparent plates were assayed for protein expression by 
sulforhodamine B (SRB) colorimetric assay after 24hr, 48hr, 36hr, and 72hr. After incubation 
of cells at 37ºC with 5%CO2, the plates were taken out and medium is discarded. 10% (w/v) 
TCA was added to the wells and the plates were incubated at 4ºC for 2 hours to fix the cells. 
TCA is then discarded and the plates were rinsed with water and dried at 37ºC for 20 
minutes. 0.05% (w/v) of SRB reagent was added to the wells and the plates were incubated 
for 30 min at room temperature in dark. The plates were washed for 3 to 4 times with 1% 
(v/v) acetic acid to remove SRB reagent and then dried for 20 minutes at 37ºC. 100 mM Tris 
was added to the plates and the plates were shaken for 10 minutes after which, the 
absorbance was measured at 570 nm from the stained cells and at 650 nm from blank after 
which, the results were tabulated for calculating the percentage of viable cells after 
transfection. The cells seeded in opaque plates were assayed for ATP using CellTiter-Glo 
Luminescent Cell Viability Assay according to the manufacturers’ protocol. All assays were 
performed with 8 technical replicates for each condition for 3 independent experiments. 
5.2.5.6. Western Blot 
10% SDS gels were used for resolving protein. 10% and 5% acrylamide/bisarcylamide were 
used respectively for resolving and stacking part of the gel. 0.06% (w/v) 
ammoniumpersulphate and 0.1% (v/v) N, N, N’, N’ – tetramethylethylenediamine (TEMED) 
were used to induce the polymerization of the gel. 10 µg of protein with rotiload loading dye 
were boiled together for 5 minutes and loaded into the respective slots in the gel. A 
prestained- protein ladder was also loaded referring to the molecular weight. Electrophoresis 
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of the gel was carried out for 90 minutes at 135 V and 500 mA in 1X SDS-gel tank buffer. 
The transfer of polypeptides from the gel to a nitrocellulose membrane was carried out by 
TE70 PWR semidry transfer apparatus. A sandwich model was prepared by soaking 
Whatman filter papers in anode buffers I, II and cathode buffer. The membrane was activated 
in anode buffer II. The stacking part of the gel was cut and the sandwich was assembled with 
the filter papers, membrane and the gel after which the semidry electrophoretic transfer was 
carried out for 60 minutes at 35 V and 500 mA. To detect the transferred protein, after the 
transfer the membrane was blocked for 1h at room temperature with the milk blocking buffer. 
After blocking, the membrane was incubated with the diluted primary antibody over night at 
4ºC. After incubation, the membrane was washed 3 times with 1XTBST and was incubated 
with secondary antibody conjugated with horse radish peroxidase for 1h at room temperature. 
Then, the membrane was washed for 3 times with 1XTBST and protein was detected by 
enhanced chemiluminescence (ECL) using the ECL prime western blot detection kit. The 
ECL substrate was prepared according to the manufacturer’s instructions and incubated on 
the membrane for 1 minute and the solution was drained off. Now, the membrane was kept 
on a clean plate inside the LAS Fujifilm 5000 machine and images were captured using a 
CCD camera on exposing the membrane gradually to the X- rays. Similarly, the procedure 
was repeated for the detection of the house keeping protein in the same membrane. 
5.2.5.7. Dual Luciferase Assays 
The target genes of hvt-miR-H14-3p are first observed to be down regulated at protein level 
by Western Blot. For validation, a dual luciferase assay system was produced. The p27 
3’UTR wild type and mutant dual luciferase vectors were kindly provided by Prof. Reuven 
Agami from the Netherlands Cancer Institute (NKI). These vectors were transformed into 
suitable chemically competent bacteria, and plasmids were isolated post overnight culture. 
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The isolated plasmids were co-transfected with viral miRNA mimic or non-targeting negative 
control into CFPAC-1 cells. Empty vector is also transfected separately to normalize the 
luciferase expression. 
5.2.5.8. Construction of Lentivirus Vectors 
The desired lentiviral plasmids were selected Addgene. These plasmids include pLKO.1 - 
TRC control as transfer vector, pCMV-VSVG as envelope vector, and pCMV-dR8.2 dvpr as 
packaging vector for second generation packaging. The scramble shRNA plasmid was also 
ordered as non-targeting control. For in vivo bioluminescence tracking of tumor progression 
in mice, pLenti CMV Puro LUC (w168-1) vector was ordered form Addgene, to amplify the 
CMV promoter and firefly luciferase gene from it and clone into, both the transfer and 
scramble vectors. The vector maps for all plasmids used in this section can be found in the 
supplementary data section. 
The hvt-mir-H14 shRNA construct was designed to be compatible with PLKO-1 lentiviral 
transfer vector system. The sense and antisense viral shRNA oligomers were designed in the 
way that following the annealing they generate AgeI and EcoRI restriction sites respectively 
in 5’ and 3’ of the construct. The annealing reaction of sense and antisense oligos was 
performed by incubation of the strands at 95°C for 5 minutes in a heating block, then slowly 
cooling down to room temperature overnight. The annealing reaction contains 100 μM of 
each of sense and antisense oligomers with 5 μL 10x NEB buffer 2 in 35 μL distilled H2O.    
To clone the shRNA into the pLKO.1 transfer vector, double digestion using AgeI and EcoRI 
Fast digest restriction enzymes was performed. The digested plasmid was purified using 5-
Prime PCR purification kit. The purified and linearized PLKO-1 plasmid was ligated with 
shRNA construct and transformed into chemically competent E.coli. To screen for the 
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recombinant plasmids, colony PCR using forward primer on the shRNA construct and the 
reverse primer on the plasmid sequence was performed. The recombinant colonies with 
desired sequence were cultured; plasmid was purified, and sent for sequencing to confirm the 
right clones. The next step was to clone the CMV-Luc gene sequence into the both PLKO-1-
shRNA and scramble control vectors. The ClaI enzyme, that cuts the insertion site in the 
plasmid, is blocked by CpG and dam methylation. Hence, both plasmids were transformed 
into the K12 E.coli, and the plasmids were unmethylated in this strain of E.coli. The CMV-
Luc sequence was amplified from pLenti CMV Puro LUC (w168-1) and cloned into PLKO-1 
and scramble vectors using in-fusion cloning system from Invitrogen.  After the ligation and 
transformation, positive clones were selected by colony PCR and confirmed by single read 
sequencing.  
5.2.5.9. Production of Lentiviral Particles 
Seeding cells: HEK293T were seeded in DMEM, 10% FCS, no PS, with fresh L-Glutamine 
(4 mM) added at 350.000-500.000 cells per well of a 6-well plate in 2 mL per well (= 17.5 x 
10
4
 cells/mL – 25 x 104 cells/mL).  
Transfection: Mastermix was prepared for packaging and envelope vectors, distributed into 
safe lock tubes. “Plasmid plus Reagent Mix” was inncubated for 15 min at room temperature. 
“Lipofectamine Mix” was added to each plasmid-mix and incubated for 15 min at room 
temperature. “Complete Mix” was added (Lipofectamine + Plasmid Mix) to each well into 
cell medium and incubated for 18hr. The transfection medium was removed carefully after 
incubation. 2 mL DMEM with 30 % FCS and 1 % P/S was added to each well. 
First viral harvest: Viral supernatant for each virus type was pooled, dead cells pelleted and 
kept at -80°C. The virus population is collected in 100 µL aliquots in PCR-strip-tubes (kept 
in a 50mL Falcon tube).  
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5.2.5.10. Transduction of Cells 
BxPC-3 and MIAPaCa-2 cells were transduced with two lentiviral populations separately. 
The transduction was enhanced by the use of polybrene transduction agent. 1 million cells 
were seeded per well in 6 well plates. The lentivirus and added to the growth medium in a 
ratio of 1:50 along with polybrene. After this procedure, the plates were maintained in 
incubation chamber at 37ºC and 5% CO2. The cells were selected for recombinants under 
puromycin selection pressure. 
5.2.6. In vivo Experiments 
Tumor xenograft experiments were carried out in NOD scid gamma mice using BxPC-3 and 
MIAPaCa-2 transduced with viral miRNA or scramble negative control. 60 million lentivirus 
transduced PDAC cells diluted in 1x PBS in appropriate volume were mixed with equal 
volume of Matrigel and subcutaneously injected into the right flank of mice. The tumor size 
(length, width and depth) was measure using the caliper. The mice cohorts with BxPC-3 cells 
were injected with D-luciferin before bioluminescence (BLI) measurements by IVIS 
Xenogen machine. Currently, these cohorts are being sacrificed 3 weeks post inoculation and 
primary tumors are also being resected.  
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